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Poxviruses are characterized by large double stranded DNA genomes that encode numerous
proteins tailored for host immune response evasion. Our lab has been investigating a sequencediverse family of secreted poxvirus proteins that appear to share a conserved beta-sandwich fold,
but differ in their immunomodulatory functions. We have termed members of this superfamily
Poxvirus Immune Evasion (PIE) proteins, and there appears to be at least 20 distinct subfamilies.
As it turns out, cowpox virus (CPXV) encodes 10 PIE proteins, one of which, M2, can inhibit
murine T cell activation through specific interactions with co-stimulatory ligands B7.1 (CD80)
and B7.2 (CD86). Functionally, we’ve shown that CPXV M2 selectively blocks murine
B7.2/CD28 interaction. Using surface plasmon resonance (SPR), I’ve demonstrated that CPXV
M2 has a preferential interaction with mB7.2 over mB7.1 which allows the predominantly
inhibitory molecule, mB7.1, to continue interaction with mCTLA-4. Cryo-EM analysis of CPXV
M2, in complex with human B7s, reveals the formation of both hexameric and heptameric ringed
structures linked via intermolecular disulfide bonds. These oligomers are constitutively
xii

expressed and secreted with the capability of binding one B7 molecule per monomer. Size
exclusion coupled light scatter, native mass spectroscopy, negative stain EM, and native PAGE
all support the formation of these oligomeric species in both B7-bound and unbound CPXV M2.
Additionally, oligomerization is conserved in at least three other poxvirus M2 analogs (MYXV,
YKV, VACV WR), each of which has their own B7 species specificity. Together, our data helps
define a novel mechanism by which CPXV exploits cellular ligands to selectively shut down host
T cell activation.

xiii

Chapter 1: Viral Immune Evasion
Research within this chapter consists of data that was published in Viruses
Nelson C, Epperson M, Singh S, Elliott J, Fremont D. Structural Conservation and Functional
Diversity of the Poxvirus Immune Evasion (PIE) Domain Superfamily. Viruses.
2015;7(9):4878-4898. doi:10.3390/v7092848
Christopher Nelson collected and processed the genomic data. The figures were constructed by
Christopher Nelson and Megan Epperson. Sukrit Singh and I helped with data analysis, literature
review, and data discussions. Christopher Nelson, Megan Epperson and Daved Fremont wrote
the manuscript.

1

1.1 Host immune response to viral infection
Vertebrate immune systems have developed into two distinct subsystems to effectively
respond to foreign pathogen such as viruses. These systems are comprised of specific cell types,
each with diverse and significant roles for host protection. The first of these subsystems, the
innate immune system, is an evolutionarily older defense strategy, and is the dominant immune
system found in many species providing immediate defense against infection1. The innate
immune system is responsible for the recruiting of cells to sites of infection using secreted
cytokine gradients, identification and removal of foreign substances using white blood cells, and
activation of the second subsystem: the adaptive immune system2–6. As the innate immune
system works to control viral replication, it will also begin to recruit and activate components of
the adaptive immune response, which will work to eliminate the viral infection and develop
resistance to future infections3. The adaptive immune system is able to confer long-lasting or
protective immunity for the host, while the cells of the innate system recognize and respond to
pathogens in a generic fashion. That long-lasting protection comes in the form of immunological
memory, so that having been exposed once to an infectious agent, a host will make an immediate
and stronger response against any subsequent exposure. That is, they will have protective
immunity against that particular pathogen1. This protective immunity is dependent upon the
activity of two antigen specific lymphocytes: B-lymphocytes (B cells) and T-lymphocytes (Tcells). Each has quite distinct roles and mechanisms of action in immune response.

1.2 Adaptive immune response to intracellular pathogens
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Adaptive immune response consists of a complicated cascade of protein-cell interactions.
In an effort to expel infectious material, but not cause irreparable harm to the host, the adaptive
immune response utilizes a delicate balance of stimulatory and inhibitory signals carried out via
cytokines and surface receptors. Intracellular pathogens pose the greatest risk as possible
detection is masked by infected host cells. B lymphocytes and T lymphocytes express unique
cell-surface receptors that allow the detection of intracellular pathogen via antigen presentation.
Explicitly, infected cells have the ability to display “non-self” biological molecules on their
surfaces as a signal for targeted cell death. Naturally, viruses have evolved numerous tactics to
bypass this presentation or block any downstream effects. Here we examine the complexities of
adaptive immunity and the roles of different immune cell types.

1.2.1 B lymphocytes and T lymphocytes are the backbone of adaptive
immunity
B cell function
B cells perform several immunological functions; however, due to their ability to produce
antibodies, they have been considered mainly as positive regulators of immune responses and
central contributors to the pathogenesis of immune related diseases7. Antibodies aid in antigen
disposal through neutralization, agglutination, opsonization, complement activation, or enhanced
activation of NK cells1. The specific action of each antibody depends on its class; therefore,
production of each class is necessary for optimal pathogen clearance. While antibody production
is widely accepted as the principle function of B cells, over the last 20 years, investigators have
attributed additional functions to B cells. These functions include antigen presentation, the
production of multiple cytokines, and a suppressive capacity due to their secretion of IL-108–10.
3

This composition of functions establishes B-cells as a necessary component in pathogen
clearance as well as immune system regulation.
B cell activation
B-cells can be distinguished from other lymphocytes by the presence of B-cell receptors
(BCR), essentially membrane bound antibody. The cross linking of these receptors via antigen
binding provides the first signal in T-cell dependent B-cell activation. After the initial signal,
helper T-cells that have been primed from the same antigen can interact with antigen-presenting
B-cells causing the release of cytokines that stimulate B-cell proliferation and antibody
production1. B-cells can also be activated through two T-cell independent pathways: type1 and
type2 T-cell independent activation. While both T-cell independent pathways decrease B-cell
response time to viral infections, only T-cell dependent activation can trigger germinal center
formation, isotype switching, and affinity maturation1. Additionally, because almost all memory
B cells are derived from germinal centers, effective antibody-mediated memory is compromised
by T-cell independent B cell activation.
T cell function and differentiation
T-cells differentiate into one of several different functional types of effector T
lymphocytes1,11. There are three classes of effector T-cell function: killing, activation, and
regulation. Cells infected with viruses or other intracellular pathogens are killed by cytotoxic Tcells while helper T cells provide necessary additional signals that influence behavior and
activity of other cells1,11. Lastly, regulatory T cells suppress the activity of other lymphocytes to
help control immune responses preventing autoimmune abnormalities11. Throughout the course
of an immune response, some activated B cells and T cells will differentiate into memory
cells12,13. These lymphocytes are responsible for the protective immunity that can follow
4

exposure to infection or vaccination. Upon repeat exposure to specific antigen, memory cells will
readily differentiate into effector cells thus mounting a more rapid immune response.
Cytotoxic T-cells (CD8+)
Cytotoxic T-cells provide protection by killing infected “target” cells before microbes
can proliferate and escape from the infected cell to infect neighboring cells. After recognition of
microbial antigen on the surface of an infected target cell, T-cells can focus secretory
components toward the target cell. Cytotoxic T cells can then employ at least two strategies to
kill target cells, both of which induce apoptotic cell death. CD8+ T cells usually release perforin,
a pore-forming protein homologous to the complement component C9, which polymerizes in the
target cell plasma membrane to form transmembrane channels. Stored in secretory vesicles of the
cytotoxic T cell, perforin is released by local exocytosis at the point of contact with the target
cell. These secretory vesicles also contain serine proteases, which are thought to enter the target
cell cytosol through the perforin channels, although more recent reports suggest perforin pores
may not be large enough for protein transport. One of the proteases, granzyme B, cleaves and
activates one or more members of the caspase family of proteases that mediate apoptosis10.
Through subsequent caspase cleavage, a proteolytic cascade results that helps kill the cell. In the
second killing strategy, a homotrimeric protein on the cytotoxic T cell surface, Fas ligand, binds
to transmembrane receptor proteins on the target cell called “Fas”. The binding of multiple Fas
proteins causes their cytosolic tails to cluster and recruit procaspase-8 into the complex via an
adaptor protein. The recruited procaspase-8 molecules cross-cleave and activate each other to
begin the caspase cascade that leads to apoptosis.
T-helper cells (CD4+)

5

T-helper cells are required for almost every adaptive immune response. They facilitate
activate B cells antibodies secretion and aid macrophages in destroying ingested microbes, but
they also help activate cytotoxic T cells to kill infected target cells and are necessary for memory
CD8+ T-cell maintenance. When an antigen-presenting cell activates a naïve helper T cell in a
peripheral lymphoid tissue, the T cell can differentiate into a TH1, TH2, or TH17 effector helper
cell3, 10. The task a CD4+ performs depends on the subclass the naïve T-helper cell differentiates
into. These three functionally distinct subclasses of effector helper T cells can be distinguished
by the cytokines they secrete and function they perform.
A TH1 differentiated cell will secrete interferon-γ (IFN-γ). tumor necrosis factor-α (TNFα), and activate macrophages to kill microbes located within macrophage phagosomes. In this
way TH1 cells help control bacteria that set up intravesicular infections in macrophages. These
bacteria are taken up by macrophages in the usual way but can evade the killing mechanisms
once inside the cell. When a TH1 cell recognizes bacterial antigens displayed on the surface of an
infected macrophage, it will interact with the infected cell to activate it further, stimulating the
macrophage's microbicide activity enabling it to kill resident bacteria3. While TH1 helper cell
function mostly aids in clearance of intracellular pathogen, TH1 cells may also stimulate B cells
to secrete IgG antibodies capable of coating extracellular microbes and activating complement.
If the naïve T helper cell differentiates into a TH2 cell, it will secrete interleukins 4, 5, 10, and 13
(IL-4, IL-5, IL-10, and IL-13) and will mainly defend the host against extracellular pathogens3, 10.
Cytokines produced by TH2 cells are required for antibody class switching in B cells to produce
the IgE class of antibody, the primary role of which is to fight parasite infections. IgE is also the
antibody responsible for allergies mediated through their binding of mast cells, basophils, and
eosinophils3, 10.
6

The third subclass of T-helper cells is the TH17 cells. These cells seem to be induced
early in adaptive immune responses and provide help for protection against extracellular bacteria
and fungi through stimulating the neutrophil response that helps to clear such pathogens14–16.

1.2.1 MHC antigen presentation and T lymphocyte activation
T cells require multiple signals to become fully activated against infection (Figure 1).
Antigen specific signal is delivered through the T cell’s surface antigen receptor (TCR)
following engagement with “non-self” peptides. These peptides are presented on surfaces of
antigen presenting cells (APCs) by major histocompatibility complex (MHC) receptors17,18.
There are two types of MHC molecules: MHC I and MHC II. While both are capable of
presenting pathogen-specific peptides to T cells during infection, antigen is obtained via two
distinct pathways19. MHC I typically presents cytosolic antigenic peptides that have been
degraded by intracellular proteasomes. These peptides are then translocated into the endoplasmic
reticulum (ER) by transporter associated with antigen presentation (TAP). Here peptides can
load recently translated MHC I headed for the cell surface. MHC II molecules typically load
peptides following phagocytosis and digestion of extracellular material. However, crosspresentation links the two pathways resulting in MHC I presentation of extracellular antigens20.
Similarly, cytosolic proteins can be presented by MHC class II molecules when degraded
through autophagy or other pathways via cross-dressing21

Following MHC-antigen presentation to T cell receptors, an additional “co-stimulatory”
signal is necessary for optimal immune response. This signal is achieved through a second Tcell surface co-receptor, CD28. T cell CD28 engages a separate set of co-stimulatory ligands
7

presented on APC surfaces22,23. Initially it was believed that CD28 interacted with one costimulatory ligand on the APC surface termed B7 (B7.1, CD80), however, an additional ligand,
appropriately termed B7.2 (CD86), was discovered to also induce CD28 co-stimulation in B7.1
deficient mice24,25. Additionally, upon activation, T cells express another surface receptor,
CTLA-4, that also engages B7.1 and B7.2 ligands. CTLA-4 acts to outcompete CD28 for binding
both ligands with at least 10 fold greater affinity26–29 (Figure 2).

However, while CD28

functions to activate T cells, CTLA-4 has an inhibitory affect and serves as a checkpoint control
of T cell activation28–30 (Figure 3). In addition to variation in kinetic properties it is also known
that CD28 and CTLA-4 interact with B7 ligands with different stoichiometric properties. CD28
and CTLA-4 are both cell surface receptors expressed as cysteine linked homodimers of 2 single
immunoglobulin domains; however, CTLA-4 binds bivalently to B7.1 and B7.2 while CD28
interacts in a monovalent fashion with both ligands27,31–33. Another layer of complexity comes
from the differences between B7.1 and B7.2 in both organization and expression. While both B7
ligands are type 1 transmembrane proteins with a distal IgV and proximal IgC domains, B7.2
exist as a monomer on APCs surfaces and B7.1 self associates to form a homodimer34–36. B7.2 is
also constitutively expressed on APCs while B7.1 is not, but both B7.1 and B7.2 can be rapidly
up-regulated37,38. The early constitutive expression of B7.2 on APCs along with the knowledge
that CD28 is constitutively expressed on T cell surfaces, while CTLA-4 is up-regulated post
activation, has led to the hypothesis that B7-2 may be more important for successful initiation of
T cell response39.

1.3 Poxvirus immune evasion strategies
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Naturally, viruses have evolved to employ many different tactics to evade host immune
detection. Poxviruses comprise a diverse family (poxviridae) of large double-stranded DNA
viruses. An absolute intracellular pathogen, these viruses undergo replication exclusively in the
host–cell cytoplasm. Out of the typical 200 or so open readin frames (ORFs)40, poxviruses only
encode ~50 proteins necessary for virion assembly, transcription, and DNA replication41. These
ORFs are well conserved in genome positioning and sequence across different species. The
remaining ORFs are more variable and likely encode factors that confer virulence, tissue
tropism, or serve to expand host range42. While some studies suggest that poxviruses have
evolutionarily captured host genes that aid in immune detection evasion, sequence comparison of
ORFs across different genomes show that poxviruses also adapt to changes in host defense by
altering their existing repertoire43,44.
Recent computational analysis of reported poxvirus atomic structures has revealed that
several poxvirus proteins adopt a unique β-sandwich fold, despite sharing no sequence
similarity45. The structure of soluble secreted cowpox virus chemokine inhibitor, vCCI, provided
the first model in which this domain was visualized46. Since then, many analog structures for
poxvirus vCCI proteins have been solved and confirm the domain conservation within the vCCI
subfamily. However, the structure for vaccinia A41, another chemokine binding protein, was
solved and subsequently found to have a β-sandwich fold very similar to that of vCCI47. Initially,
it was believed that poxviruses potentially utilize this unique fold as a core domain for
chemokine decoy receptors. By mutating decorations surrounding core domain, the protein
chemokine specificity could easily be altered by the virus and would allow for a broad decoy
receptor repertoire. However, crystallographic studies revealed that cowpox virus protein,
CPXV203, a member of the T4 family, also adopts a β-sandwich fold similar to poxvirus
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chemokine binding proteins. This is of significant interest as CPXV203 does not bind
chemokines, but instead blocks MHC class I surface expression48–51. The data currently available
would then suggest that the use of this core domain is not restricted to chemokine subversion, but
is potentially used for greater immunomodulatory functions that aid in viral immune evasion.

1.3.1 Many poxviruses produce molecules to enable chemokine/cytokine
subversion
Migration of leukocytes to sites of infection are mediated by chemotactic cytokine
gradients (Chemokines). These small, often negatively charged, proteins are released at points of
injury or infection and form gradients by binding to cell surface and extracellular matrix
glycosaminoglycans (GAGs).

Receptor-bearing immune cells can subsequently follow this

gradient of increased chemokine concentrations towards infection sites. Expectantly, poxviruses
have evolved proteins to disrupt chemokine networks52. These proteins are conserved in many
poxvirus species and are typically expressed during the early stages of viral infection53,54. One
class of CC-chemokine-binding viral proteins were initially classified as viral chemokine binding
proteins (vCKBPs) but have sense been simply classified as the vCCI subfamily45. Since the
discovery of the first vCCI protein in cowpox virus46, many poxvirus analogs have been solved
from rabbitpox, myxoma, and ectromelia viruses37,53,55. While incapable of solely bocking
chemotaxis, A41 and E163 are two other poxvirus proteins that bind CC-chemokines47,56.
Interestingly these proteins are distantly related to the vCCI; however, structure studies reveal
very similar topologies between the two protein subfamilies. Proteins sharing this classification
are grouped into the A41 subfamily for poxvirus immune evasion proteins.
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In addition to impeding chemotaxis via direct interaction, some poxvirus proteins act on other
significant cytokines to aid virus in immune evasion. To that end, many poxvirus encode TNF
decoy receptors that are secreted during infection57,58. These proteins serve to block TNFmediated chemokine/cytokine production. Appropriately termed cytokine response modifiers
(Crms), the GRI cowpox virus strain encodes four Crm paralogues alone (CrmB, CrmC, CrmD,
and CrmE). While completely missing in some vaccinia strains, variola (smallpox) and
monkeypox viruses encode a CrmB analog, while ectromelia encodes only CrmD59–62. While all
Crm proteins display a cysteine-rich N-terminal domains common to TNF receptors, both CrmB
and CrmD contain an approximately 160 amino acid C-terminal domain that is distinct from the
TNF-binding region. Upon further analysis it was determined that this c-terminal region is
conserved in three other poxvirus proteins. Due to their ability to bind chemokines, this domain
was termed smallpox virus-encoded chemokine receptor or SECRET domain63. The three
identified proteins were thus named SECRET-containing proteins SCP-1, SCP-2, and SCP-3.
While no structure for the SCPs is yet available, it was predicted that the SECRET domain of
SCPs and CrmB would have structural similarity to vCCI and A41, despite low sequence
similarity (Figure 4). the crystal structure of ECTV CrmD in complex with CX3CL1 provided
the evidence necessary to confirm this prediction for Crm poxvirus proteins64.

1.3.2 Poxviruses express proteins that serve to downregulate MHC antigen
presentation
As mentioned earlier, cowpox encodes a protein that serves to prevent T cell- mediated
killing of infected cells via downregulation of antigen presenting MHC molecules. CPXV203,
encoded by ORF CPXV_BR_203, acts synergistically with CPXV012 to reduce MHC I
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presentation48. While CPXV012 blocks TAP-mediated transport of antigenic peptides into the
ER, CPXV203 exploits ER-mediated protein retention via a c-terminal KTEL motif50,51,65,66.
Explicitly, CPXV203 binds MHC molecules in a pH dependent manner where binding efficiency
is significantly improved as vesicles transverse the Golgi and vesicular environments become
more acidic. The naturally occurring KDEL recycling pathway67, employed to capture defective
chaperone-complexed MHC class I proteins, then leads to CPXV203’s retrograde transport back
to the ER. Associated MHC molecule is also transported, but released once inside ER due to pH
increase, restarting the cycle. Interestingly, crystallographic analysis revealed that CPXV203 is
structurally related to the poxvirus chemokine binding proteins vCCI and A4151 (Figure 4). This
unique subfamily of poxvirus proteins has been termed the T4 family. Naturally, other members
of the orthopoxvirus T4 family also contain a C-terminal KTEL motif, and presumably interact
with the KDEL-receptor. T4 family members are found in leporipoxvirus, cervidpoxvirus, and
caporipoxvirus, demonstrating their significance for immune evasion. The observation of one
uniquely conserved β-sheet fold in proteins of varying immunomodulatory function was
interesting. Therefore, our lad set out to fully characterize this large family of poxvirus proteins
and their distinct functionality.

1.3.3 Poxvirus Immune Evasion (PIE) domain and the PIE protein family
In each case described above, poxviruses use the shared β-sandwich domain for varying
immunomodulatory functions. For this reason, we here propose calling the conserved β-sheet
domain, the poxvirus immune evasion (PIE) domain. Sorting proteins based on domain structure
can be especially powerful in identification of the poxvirus proteins. Often, structure is
conserved at a level higher than sequence and allows biophysical properties to be compared
12

across protein families. This is done in an effort to identify features that differ and are likely to
confer unique host-virus interactions leading to diverse immunomodulatory functions. Recently,
we set out to search for additional members of this family, especially among ORFs of still
unknown function. Our lab examined 33 representative chordopoxvirus genomes to find PIEdomain-containing proteins. A combination of methods was used to detect possible PIE domains.
A hidden Markov model of the PIE domain core was constructed by removing the decorations
from the alignment using the HMMER68 web server (Figure 4). This Markov model was then
used to screen genomic sequences. Blastp69 was also used to screen genomes with existing PIE
amino acid sequences. Phyre270 was used to classify potential PIE ORFs if they contained a
signal peptide and threaded to any of the known PIE structure. The ~150 potential PIE proteins
are extremely sequence diverse, and are further classified into 20 separate families across seven
genera (Table 1). All appear to contain a β-sandwich core domain, but each family is decorated
by a unique set of insertions that encode varying secondary structural elements (Figure 4).
Following this analysis, it is clear the members of the PIE family are functionally diverse,
interacting with immune system components not restricted to chemokine function. Being able to
structurally analyze these PIE proteins has allowed for significant novel discoveries. Simple
sequence of analysis of representative PIE subfamily members provides no readily obvious
information pertaining to their function (Figure 5); however, when structural elements are taken
into consideration, well supported predictions can be made about their diverse roles. This
diversity is sure to increase as more structures are solved and unknown PIE protein function is
elucidated.
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1.4 Figures & Tables

In addition to antigen presentation, T cells require costimulatory signal through CD28/B7
interaction for full activation: T helper CD4+ (left) and cytotoxic CD8+ (right) cells require
the same signals for activation.
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Binding affinities of human T cell coreceptors to their B7 ligands: CTLA-4 binds both
B7.1&2 molecules with 5-10-fold higher affinity in comparison to CD28
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Following activation, CTLA-4 is upregulated and out competes CD28 for binding B7
molecules thus inhibiting T cell activation: Both CD4+ and CD8+ T cells upregulate CTLA-4
to regulate T cell activity. The CTLA-4/CD28 axis serves as a system of check and balances for
T cell activity.
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Structures of known immunomodulatory poxvirus proteins reveal conservation of unique
β-sandwich domain: The poxvirus immune evasion (PIE) domain structures adopt a strikingly
similar fold despite considerable sequence diversity. Strands in the β-sandwich core domain
(cyan) are numbered the same for all four structures to aid comparison. The decorations unique
to each structure (dark blue) are labeled (h for helix, β for strand). CPXV203 does not contain a
strand β11 in sheet I. Similarly, strand β8 of sheet II is absent from vCCI and A41. The disulfide
bonds are labeled in red (A–E). All ribbon diagrams are shown in the same orientation and at the
same scale. Structures displayed include: rabbitpox vCCI (PDB ID: 2FFK)71, cowpox CPXV203
(PDB ID: 4HKJ)51, vaccinia A41 (PDB ID: 2VGA)47, and ectromelia CrmD C-terminal SECRET
domain (PDB ID: 3ON9)64.
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Sequence alignment of poxvirus protein representatives from each PIE subfamily:
Sequence alignment of representative members of the PIE families. The positions of the vCCI
core strands (cyan) are shown above the sequences. Cysteines are boxed in yellow.
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Poxvirus strain distribution of PIE and predicted PIE domains
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Chapter 2: Cowpox M2 binds B7.1 and B7.2
and effectively hinders T-cell costimulation in
mice
The research within this chapter consists of data that are published in Proceedings of the
National Academy of Sciences of the United States of America.
Xiaoli Wang, Sytse J. Piersma, Jabari I. Elliott, John M. Errico, Maria D. Gainey, Liping Yang,
Christopher A. Nelson, Wayne M. Yokoyama, Daved H. Fremont. Cowpox virus encodes a
protein that binds B7.1 and B7.2 and subverts T cell costimulation. PNAS. October
2019:201909414. doi:10.1073/pnas.1909414116
Xiaoli Wang, Sytse Piersma, and Daved Fremont wrote the manuscript. Xiaoli Wang performed
the FACS and in vitro experiments. I expressed and purified the recombinant M2 protein used in
in vitro experiments. Xiaoli and I performed the viral infection, ex vivo experiments. Sytse
Piersma performed the viral infection, in vivo experiments.
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2.1 CPXV M2 specifically binds human and murine B7.1
(CD80) and B7.2 (CD86).
Cowpox PIE proteins with unknown function were screened for interaction with surface
molecules of various immune cell lines. CPXV M2 was discovered to interact with both human
and murine B-lymphoblast and DC cell lines. Ultimately, it was revealed that CPXV M2 binds
human B7.1 and B7.2 expressed on these cell surfaces. Fibroblasts transduced to express either
human or murine B7.1 or B7.2 were then analyzed for cell-surface staining by CPXV M2. These
analyses concluded that CPXV M2 binds cell surface B7.1 and B7.2 from both human and
mouse. To examine specificity of the viral protein, fibroblasts expressing other B7 family
members were also tested for M2 surface staining. Negative interaction with these cell surfaces
demonstrates CPXV M2’s specificity for B7.1 and B7.2 costimulatory molecules.

2.1.1 Identification of B7.1 and B7.2 as ligand candidates for CPXV M2
His-tagged CPXV M2 was recombinantly expressed using the mammalian 293F cell line.
Fluorescence activated cell sorting (FACS) was then used to determine cell lines that bind
biotinylated CPXV M2 (bio-M2). M2 was shown to interact with cell surfaces of murine Blymphoblast cell lines CD27 and Raji, human B-lymphoblast cell line RPMI8866, and the
murine DC cell line DC2.4 (Figure 1A). However, no significant surface interaction was
observed between M2 and fibroblast cell lines from human or mouse, nor human and murine Tlymphoblast cell lines (Figure 1A). These findings suggest that CPXV M2 specifically interacts
with surface molecules expressed on antigen presenting cells (APCs). To elucidate which
specific APC surface receptors CPXV M2 interacts with, mass spectroscopy (MS) was
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employed. The human B lymphoma cell line, RPMI8866, was chosen for co-precipitation and
tandem MS analysis (Figure 1B). RPMI8866 cells were lysed and then incubated with bio-M2
and neutravidin (NA) beads. Unbound molecules were then washed from NA-resin and unknown
bound ligands were digested for MS analysis. B7.1 and B7.2 were the top hits for both the gel
digestion and in solution digestion and were the only cell surface associated proteins consistently
observed in subsequent experiment repeats (Figure 1B). This is of significance as B7.1 and B7.2
are known to be expressed mainly on APCs, but not fibroblasts33, further distinguishing them
from other co-precipitated membrane proteins.

2.1.2 CPXV M2 specifically binds B7.1 and B7.2 of the B7 costimulatory
molecule family
To validate B7.1 and B7.2 as ligand candidates for CPXV M2, mouse embryonic
fibroblasts (MEFs) were transduced to express human or murine B7.1 (MEF-h/mB7.1) or human
or mouse B7.2 (MEF-h/mB7.2). Surface expression was verified using cell-surface staining with
B7-specific antibodies (Figure 2A, top). FACS analysis shows that M2 binds MEF cell surfaces
expressing both human and murine B7.1 and B7.2, but shows no interaction with the precursor
MEFs (Figure 2A, bottom). To examine M2 specificity for B7.1 and B7.2, analogous
experiments were conducted using other B7 family members that share similar ectodomains with
the costimulatory molecules. Human B7-H2, B7-H3, B7-H4, B7-H6, and murine PD-L1 and PDL2 were transiently expressed in CHO or 293T cells and incubated with bio-M2 (Figure 2B).
These experiments clearly indicate that CPXV M2 specifically binds B7.1 and B7.2 of the B7
costimulatory family.
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2.2 CPXV M2 displays preferential blockade of murine
CD28/B7.2 interaction.
Initially it was theorized that B7.1 and B7.2 have redundant functions; however, it is now
proposed that B7.1 and B7.2 vary in binding preference of T cell surface receptors CTLA-4 and
CD28. Consequently, this results in B7.1 and B7.2 having predominantly different signaling
outcomes. Explicitly, murine B7.1 (mB7.1) preferentially interacts with murine CTLA-4
(mCTLA-4) and is thus inhibitory, while mB7.2 seems to be required for initial T cell
activation31. Experiments showing that anti-mB7.2 treatment of NOD mice protects from
diabetes whereas anti-mB7.1 accelerates the disease process supports the current theory72. It has
also been shown that antigen-dependent expansion of transferred CD4+ T cells is enhanced by
anti-mB7.1 and partially inhibited by anti-mB7.232. Lastly, cell surface mB7.2 is detectable 6
hours after stimulation with LPS, while mB7.1 is not detectable until 16 hours poststimulation39,73,74,75. This data in combination with what is known about constitutive low level
expression of B7.2 on APCs, has led to the idea that B7.2 may play a larger role in initiation of
immune response while B7.1 is primarily regulatory76,77.
The notion of varying roles between B7.1 and B7.2 is of significance as it was observed
that CPXV M2 potently blocks mCTLA-4 and mCD28 interaction with mB7.2 but shows only
slight interference of mB7.1 costimulatory interactions. By selectively hindering mB7.2
interaction, M2 specifically targets T cell activation allowing mB7.1-mediated check point
control to continue. Keeping in mind that cowpox virus is native to rodent populations,
interestingly, CPXV M2 significantly blocks human B7.1 and B7.2 (hB7.1/2) interactions with
both human CTLA-4 and CD28 (hCTLA-4/CD28). To be noted, hCD28 interaction is more
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severely inhibited than hCTLA-4, presumably due to hCTLA-4’s higher affinity for hB7.1&2 as
compared to hCD2827,29. These studies indicate an increased specificity for evading murine T
cell response by selectively hindering activation via mB7.2 blockade. While the same selectivity
is not observed between hB7.1 and hB7.2, M2 seems to block human costimulatory interaction
more potently than their murine counterparts.

2.2.1 CPXV M2 blocks murine CD28 and CTLA-4 interaction with mB7.2
but displays little effect on mB7.1 binding by host coreceptors.
Due to the seemingly varying roles of B7.1&2, CPXV M2’s engagement with the
costimulatory molecules was further explored. The precise interaction between M2 and B7.1&2
was examined via competition with their respective antibodies for cell surface staining. MEFmB7.1 cells pre-incubated with the highest concentration of M2 showed very little difference in
relative anti-mB7.1 surface staining in comparison to the control, in which no M2 was present
(Figure 3A). However anti-mB7.2 surface staining was reduced in a M2 concentration
dependent manner, with a significant difference observed when MEF-mB7.2 cells were preincubated with the highest concentration of M2 (Figure 3A). These findings suggest a
preferential interaction with mB7.2 over mB7.1 for CPXV M2. While epitopes of mB7
antibodies are not known, both can block T cell coreceptor stimulation. Differences observed in
M2 blockade of anti-mB7.1 vs anti-mB7.2 imply that the viral protein may distinctively hinder
coreceptor engagement of mB7.2 vs mB7.1. Expectantly, M2 effectively interrupts soluble
mCD28-Fc interaction with surface mB7.2 with less efficient competition observed against
soluble mCTLA-4-Fc (Figure 3B). Furthermore, M2 only moderately inhibits mCD28-Fc
surface staining of MEF-mB7.1 cells and shows no effect on surface staining by mCTLA-4-Fc
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(Figure 3B). Together, this data points out a unique mechanism in which M2 primarily obstructs
the stimulatory interaction between CD28 and B7.2 while allowing the inhibitory CTLA-4/B7.1
interaction to continue unchecked.

2.2.2 CPXV M2 effectively blocks human CD28 and CTLA-4 interaction with
both hB7.1 and hB7.2.
To explore potential for future therapies, CPXV M2’s ability to block human T cell
coreceptors’ engagement of B7.1 and B7.2 was also investigated. Similar to murine experiments,
MEF cells transfected to express hB7.1/2 were preincubated with M2 before staining with
soluble hCTLA-4-Fc or hCD28-Fc (Figure 3C). While hB7.1 and hB7.2 interaction with
costimulatory receptors were robustly and equally blocked by M2, a greater affect was seen on
hCD28 binding in comparison to hCTLA-4. While this blockade doesn’t seem as selective as in
the mouse system, with respect to B7.1 vs B7.2, the preferential binding of CTLA-4 over CD28
by B7 molecules still allows M2 to act in a way that provides promise as an
autoimmune/transplant therapeutic.

2.2.2b The presence of CPXV M2, at mild concentrations, increases hPD-L1 interaction with
MEF-hB7.1 cell surfaces.
In addition to CD28 and CTLA-4, PD-L1 has been identified as a third ligand for
B7.178,79. While PD-L1 is believed to primarily engage PD-1, it potentially serves as a
supplementary ligand for B7.1-mediated T-cell inhibition. Notably, the interaction between B7.1
and PD-L1 appear to predominantly occur in cis on the cell surface, potentially optimizing T cell
regulation80,81. Due to PD-L1’s crucial role in immunosuppression, these newer findings related
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to B7.1, and CPXV M2’s role in B7 blockade, the impact of the viral protein on the interaction
between PD-L1 and cell-surface B7.1 was assessed. Here, MEF-hB7.1 or MEF-mB7.1 cells were
incubated with soluble, respective human or mouse PD-L1-Fc and ranging concentrations of M2.
Flow cytometry was then used to detect fluorescence conjugated anti-Fc antibodies following
their subsequent incubation with PD-L1-Fc stained cells. Remarkably, it was observed that the
when M2 is present, MEF-hB7.1 cell-surface staining by hPD-L1-Fc dramatically increases
(Figure 3D). Interestingly, this increase was repeatedly most prevalent at medium concentrations
of the viral protein. Further confounding, mPD-L1 shows negligible, increased surface
interaction with MEF-mB7.1 cells when M2 is present (Figure 3D). Given M2’s differences in
coreceptor blockade of hB7.1, hB7.2, and mB7.2 vs mB7.1, its plausible the differences seen
here are a result of less efficient binding to mB7.1 by CPXV M2.

2.3 CPXV M2 functions to undermine B7-mediated
costimulation and significantly alters T cell responses.
Previously, M2’s effect on T cell coreceptor interaction was assessed with no functional
readout. Here we examine the functional implications of M2/B7 interaction on T cell activation.
In the presence of recombinant CPXV M2, T cell activation assays were conducted in which
murine T cells were co-incubated with MEF-mB7.1/2 cells. Normally, proliferation and IL-2
production are upregulated following T cell coreceptor stimulation. As expected, M2’s
interaction with B7 molecules leads to significantly restricted proliferation and IL-2 production
with a greater blockade of mB7.2-mediated activation observed vs mB7.1.

To probe the

physiologically relevant activity of M2 in the context of viral infection, we engineered a cowpox
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virus incapable of expressing and secreting M2 (∆M2 CPXV). Fittingly, it was observed that M2
is necessary for alteration of infection-induced T cell responses. Supernatant from Vero cells
infected with ∆M2 CPXV shows no effect on T cell activation; however, wild-type virus (WT
CPXV) infected cell-supernatant significantly blocks T cell IL-2 production in a time-postinfection dependent fashion. Furthermore, during murine infection, ∆M2 CPXV infection elicits
a 2-fold higher cowpox specific-CD8+ T cell response when compared to wild type infection.
IFN𝛾 production by these same cells was also restricted for WT CPXV infected mice in
comparison to mice infected with ∆M2 CPXV. Similarly, the percentage of poxvirus-specific,
IFN𝛾-positive CD4+ T cells in mice infected with ∆M2 CPXV was twice as high as WT CPXV
infected mice. Taken together, the ex vivo and in vivo data indicates that M2 expressed during
cowpox infection can hinder T cell activation and interferes with expansion of poxvirus specific
CD4+ and CD8+ T cells.

2.3.1 Ex vivo experiments demonstrate CPXV M2’s ability to thwart B7
mediated T cell activation
A series of T cell activation assays were conducted to substantiate M2’s proposed role in
T cell costimulation blockade. T cells, isolated from spleens of C57BL/6 mice, were co-cultured
with mB7.2 expressing MEFs in the absence or presence of M2 (Figure 4). Co-culture was
performed in plates coated with suboptimal anti-CD3ε for necessary basal TCR activation. 4872hrs post incubation, T cell proliferation, a functional readout of activation, was quantitated
using flow cytometry. Following co-culture with MEF-mB7.2 cells, CD4+ T cells significantly
proliferated as indicated by dilution of intracellular CFSE dye. Due to anti-mB7.2’s ability to
ablate this proliferation, its definitively clear that mB7.2 expression mediated T cell response.
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Likewise, M2 addition to co-culture results in similar levels of inhibited CD4+ T cell
proliferation (Figure 4A). IL-2 production, a functional reporter measurable by ELISA analysis,
is also drastically reduced when M2 is present in splenic T cell/MEF-mB7.2 co-culture (Figure
4B, right). Like CD4+ T cell proliferation, IL-2 production of splenic T cells exposed to M2 is
reduced to levels similar to that of mB7.2 blocking antibodies. Comparatively, M2 appears less
efficient in interfering with mB7.1-mediated IL-2 production (Figure 4B, left). These findings
are consistent with earlier results demonstrating M2’s preferential blockade of cell-surface
mB7.2 costimulatory interactions over mB7.1. While mB7.2 is predominantly responsible for T
cell activation, mB7.1 engagement with CD28 can also drive an activating T cell response and
can be expressed along with mB7.2 on APC surfaces. For this reason, B7 expressing MEFs were
replaced with CH27 B cells, capable of expressing both mB7.1 and mB7.2, and T cell activation
assays were repeated. In this setting, M2 again reduces relative IL-2 production; however, to
levels below anti-mB7.2 and equal to mCTLA-4-Fc exposed cells (Figure 4C). This suggests
that M2 has the capacity to sabotage T cell costimulation mediated by both B7.1 and B7.2,
leading to an additive inhibitory effect. To thoroughly inspect M2’s physiological relevance to
cowpox immune evasion, bacteria artificial chromosome (BAC)-derived wildtype or ORF40deleted cowpox viruses (WT or ∆M2 CPXV) were engineered using en passant mutagenesis via
Red Recombination82. Replacing recombinant M2, we used supernatants collected from Vero
cells infected with either WT or ∆M2 CPXV in co-culture T cell activation assays. Suppressed
IL-2 production was apparent as early as 12 hours post exposure for WT CPXV infected cell
supernatants, but not for supernatant of ∆M2 CPXV infected cells (Figure 4D). This data clearly
demonstrates that M2, encoded by ORF40 of CPXV, is secreted by cowpox infected cells at a
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threshold sufficient for impeding mB7-2 mediated T cell activation and supports the notion for
an adaptive immune response modulating function of the viral protein.

2.3.2 During CPXV infection in vivo, M2 significantly alters CD4+ and CD8+
T cell responses.
To define M2’s capacity for subverting T cell responses during viral infection in vivo,
C57BL/6 mice were infected via peritoneum injection with either WT or ∆M2 CPXV. Using
enumeration of B8R-tetramer stained CD8+ T cells from spleens of infected mice, it was
determined that ∆M2 CPXV elicited a nearly 100% increase in B8R-specific CD+8 T cell
response relative to WT CPXV (Figure 5A). As B8R is a robust CPXV-specific antigen peptide,
these findings imply that M2 is necessary for optimal modulation of adaptive immune response.
Additional analysis reveals a similar modulation of IFN𝛾 production by CPXV-specific CD8+ T
cells upon ex vivo stimulation with ∆12∆203 CPXV-infected DC2.4 cells (Figure 5B). Similarly,
a nearly 2-fold increase in the percentage of IFN𝛾-positive CD4+ T cells was observed in mice
infected with ∆M2 CPXV as compared to WT CPXV infected mice (Figure 5C). To be noted,
increased antigen load could not cause increased T cell responses as ∆M2 CPXV titers were
slightly lower than WT CPXV titers (Figure 5D). CPXV-specific T cell response requires B7mediated costimulation, as CD28-deficient mice fail to generate a CPXV-specific response when
infected with WT or ∆M2 CPXV (Figure 5E). Additionally, because CPXV-specific response is
higher in C57BL/6 than CD28-KO mice during WT CPXV infection, it is noted that M2 does not
completely block CD28-mediated costimulation under conditions tested. In totality, the in vivo
data signifies M2’s role in interference with optimal CPXV-specific CD4+ and CD8+ T cell
response during infection via B7 binding.
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2.4 Materials and Methods
DNA constructs and cell lines. The cDNAs encoding mouse and human B7.1 (NM_009855.2
and NM_005191.3), B7.2 (NM_019388.3 and NM_175862.4) and mouse PD-L1 (NM_021893),
PD-L2 (NM_021396) were obtained from C57BL/10 mouse splenocytes and MOU cells, a
human Epstein-Barr virus-transformed B cell line, respectively by RT-PCR. The cDNAs were
subcloned into the pMSCV- and pMXs-based retroviral expression vectors as described
previously83. B6/WT3 murine embryo fibroblasts (MEFs; H-2b)84 and CHO (chinese hamster
ovary) cells (ATCC) were transduced by each of above retrovirus construct as described85. All
transduced cells as well as cell lines CH27 (mouse B cell lymphoma), DC2.4 (mouse dendritic
cell) and RMAS (mouse T cell lymphoma), MRC-5 (human fibroblast), Raji and RPMI8866
(human B lymphoma), Jurkat and CCRF-CEM (human T lymphoblast), U937 and THP-1
(human monocyte) from ATCC were maintained in complete RPMI 1640 supplemented with
10% fetal calf serum (HyClone). The constructs expressing the other B7 family members
including pCMV.SPORT6.huB7-H2 (NM_015259.5), pEF6.huB7-H3 ∆cytoplasmic tail
(NM_001024736.1),

pCMV3flag-huB7-H4

(NM_024626.3)

and

pCMV3flag-huB7-H6

(NM_001202439.2) were a gift of Dr Marco Colonna.

Protein production, purification and biotinylation. The cDNA for M2 (CPXV040 ORF;
GenBank: AGZ00972.1) was PCR amplified from CPXVBR-infected Vero cells and cloned in the
mammalian expression vector pFM1.286 with a 6His tag fused in frame at the C-terminus. M2
protein was purified from supernatant of pFM1.2-M2 transfected Expi293F cells 72 h post
transfection using nickel agarose beads (Goldbio) followed by size-exclusion chromatography on
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a HiLoaD 26/60 Superdex 200pg column (GE Healthcare). An aliquot of the purified protein
was biotinylated using EZ-Link NHS-PEG4-Biotin (Thermo).

Antibodies and reagents. Antibodies to human B7.1 (clone L307.4), mouse B7.2 (clone GL1),
mouse B7.1 (clone 16-10A1) and isotype controls were obtained from BD Pharmingen or
eBioscience, while anti-human CD86 (clone BU63) and flag (M2) antibodies were from
Serotech and Sigma, respectively. The recombinant mouse and human CD28 and CTLA4 as well
as PD-L1, all fused with Fc of human IgG1 at the C-terminus except human PD-L1 fused with
Fc of mouse IgG1, were purchased from Sino Biological Inc. In flow cytometric analysis,
stainings of these Fc-fusions were visualized by Alexa Fluor488 or Alexa Fluor647 labeled goat
anti-human IgG or goat anti-mouse IgG (Life Tech) while biotinylated M2 and controls were
detected by PE-Streptavidin (BD Pharmingen) using a BD FACS Calibur.

M2 precipitation and LC-MS/MS analyses. RPMI8866 cells were lysed in lysing buffer [1%
NP40 in TBS (20 mM Tris-HCl pH 7.4, 150 mM NaCl) with 20 mM iodoacetamide (IAA) and
complete protease inhibitors (Roche)] on ice for 1 hr. The lysate was excluded of debris and
nuclei by centrifugation at 18,000 g for 15 min and precleared with NeutrAvidin agarose resin.
Precleared lysates, after dilution with TBS/IAA and protease inhibitors to 0.1% NP40, were
incubated with 100 nM bio-M2 or bio-PIE control protein and NeutrAvidin Agarose resin for 2
hr at 4°C. The precipitates were eluted with LDS sample buffer (Thermo) and separated by
SDS-PAGE. The excised gel bands were reduced and alkylated prior to trypsin digestion.
Alternatively, the precipitates were eluted with 6M Urea-Tris buffer (50mM Tris, pH8.0),
reduced and alkylated prior to trypsin/Lys-C digestion (Promega) in solution as instructed. The
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digested peptides in 5% acetonitrile and 1% formic acid were analyzed by LC-MS with Dionex
RSLCnano HPLC coupled to a Q-exactive or a LTQ-Orbitrap velos Pro mass spectrometer
(Thermo). All MS/MS data were searched against the human database (Unipro.org) and
contaminants using Mascot (Matrix Science). Scaffold_4.8.2 (Proteome Software Inc.) was used
to validate the peptide and protein identification. LC-MS/MS analyses were conducted at the
Proteomics & Mass Spectrometry Facility of the Danforth Plant Science Center.

Generation of M2 deficient CPXV. CPXV Brighton Red was kindly provided by Dr. Karsten
Tischer (Freie Universität Berlin, Germany)87. CPXV040 was deleted using en passant
mutagenesis

as

previously

described82

with

the

primers

5’-

GGGATTAATCTTTGTTGGATCAGTCTCTAAGTTAACACACGTCTTACACAATAGTAC
GATGCTAGGGATAACAGGGTAATCGATTT-3’

and

5’-

TCCATTGTCTTATTGCTAATTGCATCGTACTATTGTGTAAGACGTGTGTTAACTTAGA
GACTGGCCAGTGTTACAACCAATTAACC-3’. The generated mutant (termed as ΔM2
CPXV in this study) was verified by next generation sequencing.

Ex vivo T cell activation, proliferation and IL-2 assays. Mouse splenic T cells from C57BL/6
mice were enriched by passing through a nylon wool column88. Enriched T cells were cultured at
2.5-5x105 cells/well with 0.5-1x105 cells/well MEF-mB7.1 or MEF-mB7.2 or CH27 cells in a
96-well plate pre-coated with 50 µl of 0.5µg/ml hamster anti-mouse CD3ε (clone 500A2, BD
Pharmingen). Purified recombinant M2 or unrelated PIE control, mouse CTLA4-Fc, anti-mouse
B7.2 (GL1) or isotype IgG were added in culture at the concentration specified. After incubation
at 37 °C for 48 h, IL-2 in culture supernatant was assessed by ELISA in triplicates using anti32

mouse IL-2 antibody pair (JES6-1A12 and JES6-5H4, BioLegend) for capture and detection. For
proliferation assays, the enriched splenic T cells were stained with 10µM CFSE (Life Tech) at
37 °C for 15min before co-culture with the MEF-mB7.2 cells in the presence or absence of
indicated antagonists. CFSE-dilution in the CD3+CD4+ population was analysed 3 days later by
flow cytometry. Viral culture supernatants were obtained by infecting vero cells in 24-well plate
with either WT or ΔM2 CPXV at MOI 1.0 or 0.5. The culture media were collected at 8, 12, 24
and 48h post infection, spun at 13,000 rpm for 2 hours, 0.22 µm filtered, snapfrozen and stored at
-80°C untill used.
Mice. C57BL/6 mice were purchased from Charles River. C57BL/6J and B6.129S2-Cd28tm1Mak/J
mice were purchased from the Jackson Laboratory. Age and sex-matched mice were infected at
8-12 weeks of age. Animal studies were approved by the Animal Studies Committee at
Washington University in St. Louis.

In vivo CPXV infections and post infection analysis. Mice were infected intraperitoneal with
50,000 PFU of indicated CPXV in 200 µl PBS. 5 days post-infection spleens were harvested and
splenocytes were isolated. B8R-specific CD8+ T cells were assessed ex vivo. CPXV-reactive
IFNγ-producing CD8+ and CD4+ T cells were assessed upon restimulation in vitro as described
earlier89. Briefly, DC2.4 cells were seeded at 2 x 105 cells per well in 12 wells plates in RPMI1640 (Sigma) containing 10% FBS and 55 µM 2-mercaptoethanol. To detect CPXV-specific
CD8 T cell IFNγ production, DC2.4 cells were infected for 4 hours with Δ12Δ203 CPXV that
ensures presentation of CPXV antigens on MHC-I48. For CPXV-specific CD4 T cell IFNγ
production, DC2.4 cells were loaded with the indicated peptides (Fig. S3) for 2 hours at 37ºC.
Next, 5x106 splenocytes were added and 1 hour later GolgiPlug (BD Biosciences) was added.
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After an additional 6 hours the incubation was stopped and the splenocytes were stained for flow
cytometry. First, viable cells were discriminated using fixable viability dye (Affymetrix). The
following antibodies were used for cell surface staining in 2.4g2 supernatant, CD3 (BD
Biosciences, clone 145-2C11), CD8a (Affymetrix, clone 53-6.7), CD4 (Affymetrix, clone RM45), NK1.1 (Biolegend, clone PK136), B8R Tetramer (NIH tetramer facility). For intra-cellular
staining, cells were fixed and permeabilized using Cytofix/Cytoperm solution (BD Biosciences)
and stained with anti-IFNγ antibody (Affymetrix). Samples were acquired using FACSCanto
(BD Biosciences) and analyzed using FlowJo software (Tree Star). Viral titers were determined
using quantitative PCR90
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2.5 Figures

Identification of B7.1 and B7.2 as candidate M2 ligands. (A) Cell lines were incubated with
biotin-labeled CPXVBR M2 (bio-M2) and stained by PE-streptavidin. Representative of at least
two independent flow cytometric analyses for each cell type is shown. (B) Pull-down, mass-spec
approach to find M2 ligands. RPMI8866 cells were lysed in 1% NP40 followed by incubation
with 100 nM bio-M2 or bio-PIE control and NeutrAvidin resin for 2 hr at 4°C. Precipitates were
separated by SDS-PAGE and gel bands were digested with trypsin (#1). Alternatively,
precipitates were digested in solution (#2) as described in Materials and Methods. Digested
peptides were analyzed by LC-MS/MS. B7.1 and B7.2 were the only two cell membrane proteins
reproducibly identified in M2 precipitations
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M2 specifically binds B7.1 and B7.2. (A) Mouse embryonic fibroblast cells (MEFs) transduced
to stably express mouse or human B7.1 or B7.2 were verified by specific antibodies (upper
panel) and stained by bio-M2 followed by PE-streptavidin (lower panels). (B) Upper panel: PDL1/2 transduced CHO cells were stained with bio-M2. CHO-mB7.2 cells serve as a positive
control. Lower panel: 293T cells were transiently transfected to express the indicated human B7
family members. Flow cytometric analysis was conducted 48h post transfection.
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M2 differentially blocks recognition of B7.1 and B7.2 by antibodies and the CD28 and
CTLA4 receptors. (A) MEFs transduced to express mouse B7.1 or B7.2 (MEF-mB7.1 or mB7.2) were pre-incubated with M2 at the indicated concentration before staining with 1µg/ml
anti-mouse B7.1 (16-10A1) or anti-mouse B7.2 (GL1) blocking antibodies. Quantification of
mean fluorescence intensity (MFI) of specific antibody staining in the presence of M2 relative to
no M2 from two independent experiments is shown in the bar chart (mean±SEM). (B) Cells used
in (A) were incubated with the recombinant M2 and mouse CD28-Fc or CTLA4-Fc at the
indicated concentration for 30min before CD28-Fc/CTLA4-Fc binding was visualized by
Fluorescence-labeled anti-human IgG. The representative flow cytometric plots of three
independent analyses are showed on the top panel. The bar chart on the bottom is the
quantification of three analyses (mean±SEM) showing MFI of CD28/CTLA4 in the presence of
M2 relative to no M2. (C) Same experiment as in (B) was conducted with MEF-hB7.1 and hB7.2 and soluble human CD28-Fc or CTLA4-Fc. (D) Same analyses as in (B and C) with MEFm or -hB7.1 and soluble mouse or human PD-L1-Fc were conducted in two independent assays
each with triplicates (mean±SEM).
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M2 inhibits ex vivo T cell proliferation and activation costimulated by B7.1 and B7.2. (A)
CFSE-labeled splenic T cells from C57BL/C mice were stimulated for 3 days with MEF-mB7.2
cells in medium containing 400nM M2, 1µg/ml anti-mB7.2 (GL1) or IgG control in plate precoated with 0.5µg/ml mouse CD3e antibodies. CD4+ cell proliferation was determined by
analysis of CFSE dilution in the CD3+CD4+ population. (B) Enriched splenic T cells were cocultured with MEF-mB7.1 or MEF-mB7.2 cells for 2 days in anti-CD3e coated plate. M2 and
anti-mB7.2 antibodies were used as in (A), irrelevant CPXV-PIE protein and mouse CTLA4-Fc
were used at 400nM and 50nM, respectively. The relative IL-2 production % in the presence of
M2 or controls was calculated using splenic T cells+MEF only (+medium) as 100%. The
representative of two independent analyses is shown (triplicates, mean±SD). (C) B cell line
CH27 was used as stimulator in T cell activation described in (B). (D) Culture supernatants
harvested at the indicated time points from Vero cells infected with WT or ΔM2 CPXV (MOI=1)
were used in T and MEF-B7.2 cell co-culture in T cell activation assay. The representative of
two independent experiments (triplicates, means) is shown.
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ΔM2 CPXV elicits stronger primary T cell responses than WT CPXV. C57BL/6-CR mice
were i.p. infected with 50,000 PFU WT or ΔM2 CPXV. Spleens were analyzed 5 days postinfection. (A) B8R (20-27) tetramer staining and total numbers of tetramer+ CD8 T cells. (B)
Percentage of IFNγ-producing CD8 T cells upon ex vivo stimulation with Δ12Δ203 CPXVinfected DC2.4 cells. (C) Percentage of IFNγ-producing CD4 T cells upon ex vivo stimulation
with peptide-pulsed DC2.4 cells. (D) CPXV titers in the spleen determined by DNA copy
number. (E) C57BL/6-J wildtype and CD28 deficient (KO) mice were i.p. infected with 50,000
PFU WT or ΔM2 CPXV and analyzed as in (C).
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Chapter 3: Cowpox M2 forms both hexamers
and septamers capable of 1:1 interaction with
either B7.1 or B7.2, in a manner that blocks
T-cell coreceptor binding sites
The research within this chapter consists of data that are in preparation for submission to Nature
Structural Molecular Biology.
Jabari I. Elliott, Christopher A. Nelson, Prashantkumar N. Jethva, Michael L. Gross, Daved H.
Fremont. CPXV M2 competitively blocks T cell coreceptors for binding B7.1 and B7.2
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3.1 Secreted CPXV M2 forms ring-like oligomers linked via
intermolecular disulfide bonds
Following CPXV M2 elution via size exclusion chromatography, it became immediately
clear the viral protein adopts a large oligomeric state during mammalian expression. Upon
further biochemical investigation, it was determined that CPXV M2 utilizes intermolecular
disulfide linkages to constitutively exists as a ~200kD MW oligomer. Low resolution EM also
revealed that lone M2 maintains a ring-liked organization, while native-PAGE implies the
formation of two dominant M2 species. These findings were validated through supplementary
mass spectroscopy techniques that definitely report the formation of hexamers and septamers,
consistent with P6 and P7 models generated from M2-X-ray scatter profiles. Ultimately, it was
concluded that CPXV M2 utilizes subunit-connecting disulfide bonds to sustain six and sevenmembered ring formation.

3.1.1 Expression and purification of CPXV M2 and B7 proteins.
The cDNA for M2 (CPX040 ORF: GenBank: AGZ00972.1) was PCR amplified from
CPXVBR-infected Vero cells and cloned in the mammalian expression vector pFM1.286 with a
6His tag fused in frame at the C-terminus. Endogenous signal sequence was not included as
pFM1.2 vector contains signal peptide optimized for expression. The pFM1.2-M2 construct was
introduced to Expi293F cells via Hype-5 trasfectant (Figure 1). M2 protein was purified from
supernatant of pFM1.2-M2 transfected 293F cells 72 hours post transfection using nickel agarose
beads (Goldbio) followed by size-exclusion chromatography (SEC) on a HiLoaD 26/60
Superdex 200pg column (GE Healthcare). The cDNA for murine B7.1 and B7.2 was cloned from
the pMSCV- and pMXs-based83 retroviral expression vectors used in previous studies91 to
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encompass ectodomain void of transmembrane region and endogenous signal sequence. Human
B7 protein production proceeded in a similar manner. However, instead of using PCR amplified
cDNA, geneblocks (IDT) encoding mature His-tagged ectodomains for B7.1 or B7.2. All cDNAs
were ligated into pFM1.2 vectors using Gibson Assembly92 reagents (NEB). Following 293F
transfection, individual His-B7 ectodomains were purified in the manner described above. FPLC
UV-traces for all B7 proteins show elution profiles consistent with what is seen in previous
publications27,29 (Figure 2A-D). However, CPXV M2 elution was significantly earlier than
expected for the 203aa protein predicted to have a MW of 24.5kD (Figure 2E). As this position
of elution signified a MW ~200kD, this was the first evidence of large oligomer formation by
CPXV M2.

3.1.2 Biochemical and biophysical analysis of CPXV M2 reveals the
formation of multiple oligomeric species linked via disulfide bonding.
Following size exclusion purification of CPXV M2, the viral protein was subjected to
SDS-PAGE analysis to investigate its constitutive state. M2 was incubated at 95ºC in the
presence or absence of 5% ß-ME and run on a 4-12% gradient gel (Figure 3A). Interestingly,
M2 seems to naturally form multiple high molecular weight oligomers that reduce to one ~37kD
band when ß-ME is introduced. With four predicted N-linked glycan sites, the expected
molecular weight for monomeric CPXV M2 is 24.5kD + 12kD (4 glycans at 3kD each) which is
consistent with the 37kD band observed. To determine the absolute molecular weight of soluble
CPXV M2, SEC-coupled multi-angle light scattering (MALS) analysis was implemented and
reveled an average MW of 194kD ± 0.3 for the viral protein (Figure 3B). M2 was then subjected
to native-PAGE analysis to further probe its constitutive state. With native conditions preserved
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during gel migration (no denaturant), CPXV M2 runs as two distinct species identifiable by two
separate bands (Figure 3C).

3.1.3 Low resolution structural analysis of CPXV
oligomerization findings and implies ring-like organization.

M2

supports

To visualize CPXV M2 oligomerization, the viral protein was subjected to analysis via
negative stain electron microscopy (EM). Upon imaging carbon-coated copper grids containing
M2 stained with 1% aqueous uranyl acetate, it was observed that the viral protein forms ring-like
structures with diameters of ~12nM (Figure 4A). Native-MS analysis of M2 was performed to
definitively elucidate dominant oligomeric states. To reduce heterogeneity induced by
mammalian glycosylation93,94, M2 asparagine residues in predicted N-linked glycan sites were
swapped for glutamine using gene blocks encoding the four mutations. The His-tagged deglycosylated protein (CPXV M2Gly) was expressed and purified using the same method described
above. Unlike traditional mass spectroscopy, native-MS enables investigation of large
biomolecules and complexes with the native state and associated biological functionality largely
preserved. Here, biomolecules are transferred from a condensed liquid phase to the gas phase via
electrospray ionization mass spectrometry (ESI-MS). Subjecting M2 to this analysis reveals the
formation of two dominate oligomeric states: hexamer and septamer (Figure 4B). Eight
individual peaks were analyzed for information on M2’s native state. Using the online server,
ESIprot95, CPXV M2Gly was determined to exist in two states with distinct molecular weights of
148kD and 172.5kD. With an expected monomeric MW of 24.5kD, this data provides further
evidence for the prevalent formation of a hexamer species (148kD / 24kD = 6.04) and a septamer
species (172.5kD / 24.5kD = 7.04) by CPXV M2Gly.
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Complementing previous data, CPXV M2’s small angle X-ray scatter (SAXS) profile
resembles profiles of other known ringed proteins96–98 (Figure 4C). Data was collected at the
ALS-SIBYLS beamline 12.3.199,100,101,97. Profile was generated by averaging individual profiles
from 32 frames at 3 concentrations (96 total). Analysis via PRIMUS102 gives an average gyration
radius (Rg) of 50.85Å, a max diameter (DMax) of 159.6Å, and a molecular weight of 198kD. This
data correlates well with previous SEC-MALS and negative stain-EM data. Using P6 symmetry
in DAMMIF103 and DAMAVER104 a hexamer model envelope of CPXV M2 was generated from
the averaged intensity profile (Figure 4D). Hexamer modeling resulted in a mean NSD of 0.329
and a x2 of 0.438 and clearly illustrates ring formation with center pore. Using P7 symmetry in
DAMMIF and DAMAVER a septamer model envelope of CPXV M2 was generated from the
same averaged intensity profile (Figure 4E). Septamer modeling resulted in a mean NSD of
0.433 and a x2 of 0.488 and also illustrates ring formation by CPXV M2 with a pore center mass.
Unbiased, P1 modeling resulted in ringed structure with pore as well (data not shown). Taken
together, these data strongly suggest the heterogeneous formation of rounded oligomeric
structures with six or seven subunits.

3.2 CPXV M2 binds human B7.1 and B7.2 with similar
affinity and kinetics, but shows dramatic differences
between mB7.1 and mB7.2 interactions.
One possible mechanism of action for M2 blockade of T cell costimulation is direct
competition with CD28 and CTLA-4. In addition to overlapping interfaces, this would require
CPXV M2 affinity for B7 ligands to be equivalent to or higher than that of the host coreceptors.
Here, I report findings in which CPXV M2 exhibits high affinity for human B7 ligands, possibly
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allowing for significant competition with costimulatory receptors. Interestingly, CPXV M2
displays weak affinity for both murine B7.1&2. However, CPXV M2 is capable for 300-fold
longer interaction with mB7.2 vs mB7.1. This is particularly significant when analyzed in
parallel with M2’s functional blockade data. As noticed earlier, CPXV M2 is incapable of
competing with mCTLA-4-Fc for binding surface mB7.1 and only moderately hinders mCD28Fc/MEF-mB7.1 interaction. This large discrepancy in interaction half-life lends a possible
explanation for M2’s selective inhibition of mB7.2 over mB7.1 and starts to describe,
mechanistically, how CPXV M2 judiciously blocks murine T cell activation while allowing
checkpoint control to proceed.

3.2.1 CPXV M2 binds human B7.1 and B7.2 with affinities that allow for
competition with CD28 and CTLA-4
To explore possible, direct competition with T cell coreceptors, CPXV M2 interaction
with human B7 ligands was assessed using surface plasmon resonance (SPR) (Figure 5). Using
amine coupling, recombinant M2 was immobilized to a CM5 chip with soluble hB7.1 or hB7.2
flown over the surface. Upon B7 binding, resonance response curves were recorded and
mathematically analyzed for kinetic information and detail pertaining to equilibrium of the
interaction. While M2 predominantly exists as a heterogeneous population of two oligomeric
states, response curves were fit using the Langmuir 1:1 binding model to accurately describe the
average binding affinity and allow for comparison to T cell coreceptors. Data analysis was
carried out using T200 BiaEvaluation Software 3.0105. CPXV M2 binds hB7.1 and hB7.2 with
disassociation constants of KD,Kin = 0.367uM and KD,Kin = 0.961uM respectively (Figure 6A &
6B). The reported affinities for hCTLA-4 and hCD28 binding hB7.1 are 0.2uM and 4uM
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respectively27. Similarly, hCTLA-4 and hCD28 bind hB7.2 with respective affinities of 2.6uM
and 20uM29. Therefore, the viral protein has the ability to directly compete with hCTLA-4 and
hCD28 for binding hB7.1 or hB7.2. While CPXV M2 would be more efficient in competition
with hCD28, this binding data supports the functional observation that M2 adequately
outcompetes both hCTLA-4 and hCD28 for binding hB7.1 and hB7.291.
Because CPXV M2 exist as a heterogeneous mix of hexamer and septamer species, hB7SPR binding curves were also fit using the 2:1 heterogeneous ligand (HL) model (Figure 7A &
7B). While the 1:1 model allows for a simplistic comparison between M2 and host receptor
affinity for hB7.1&2, the 2:1 HL model provides important information on the different binding
affinities observed between the two oligomeric-M2 species. While elucidating which one of the
oligomeric species has higher affinity for which B7 molecule is not possible; in both B7.1&2
interaction, one state has a slightly higher affinity for the B7 binding than the other (KD1,Kin vs
KD2,Kin). This finding is significant as it implies the possibility of an optimal M2-oligomeric state
for B7 engagement.

3.2.2 CPXV M2 interaction with murine B7.2 has a dramatically longer halflife than CPXV M2/mB7.1 interaction.
Like the human counterparts, murine B7s’ interactions with CPXV M2 were investigated
using SPR in which the viral protein was immobilized and mB7.1/2 was flown as analyte. Fitting
curves, using the Langmuir 1:1 model, demonstrates that CPXV M2 binds mB7.1 and mB7.2
with weak affinities of KD,Kin = 27.2uM and KD,Kin = 51.6uM respectively (Figure 6C & 6D).
However, kinetic analysis also reveals that the two interaction half-lives vary greatly. The
apparent half-life for the mB7.1 interaction is 0.5 seconds versus 139 seconds for mB7.2. The
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nearly 300-fold increase in longevity of the CPXV M2:mB7.2 complex explains the difference
observed in mB7 blockade and further illustrates an increased specificity of CPXV M2 function
during murine infection.
As with the human B7 response curves, the 2:1 heterogeneous ligand (HL) model was
also used to fit murine B7.1/2 curves. Again, a distinction in the two binding constants (KD1,Kin
vs KD2,Kin) is observed, implying different binding affinities for the two oligomeric states (Figure
7C & 7D). Of note, t1/2 values were derived for each individual HL-koff and averaged for
reported values. While interaction half-life varies between the two models, the kinetic trends
observed with 1:1 analysis remains present.

3.3 Cryo-EM analyses of CPXV M2 in complex with human
B7.1 and B7.2 reveal ligand-bound hexameric and
septameric states and supports theory for competitive
mechanistic action
Using high resolution Cryo-EM, with unbiased 2D class averaging, I can confidently
illustrate how CPXV M2 exists as a both a hexamer and septamer composed of six or seven
subunits. Furthermore, each monomeric subunit is capable of interaction with one B7 molecule.
Notably, hB7.1&2 residues responsible for M2 interaction create interface that directly overlaps
with the known CTLA-4 binding sites for both ligands. This provides the most significant
evidence for use of a direct competition mechanism by M2 to carry out its immunomodulatory
function of costimulation subversion. EM structure resolution also allows for identification of
cysteine residues responsible for intermolecular disulfides and thus M2 oligomerization. Due to
this oligomerization, avidity studies of CPXV M2/B7-BirA interaction provide physiologically
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important information on M2’s ability to sustain interaction with APC cell having sufficient B7
surface density.

3.3.1 Cryo-EM analysis of CPXV M2 interaction with human B7.1
ectodomain illustrates binding organization of protein complex
To assess the structural basis for the CPXV M2:hB7.1 interaction, M2 was incubated
with equal molar hB7.1 ectodomain and subjected to cryo-election microscopy (Figure 8, and
Table 1). The CPXV M2:hB7.1 complex was visualized using the FEI Titan Krios Cryo-TEM.
3331 micrographs were collected and analyzed using RELION software106,107. Following motion
correction and CTF estimation, image quality was assessed based on detected fit resolution with
a 4.5Å cutoff. Size parameters, consistent with scattering data, were used to pick particles from
the remaining 2772 images via the automated particle picker “Cryolo”108. 2D class averages were
then generated from sorting and overlaying the 677,079 individual particles. These unbiased
class averages show the formation of two distinct M2 oligomeric rings, hexamers and septamers
(Figure 8A). Several orientations of both hexameric and septameric complexes are visible in 2D
class averages. Class averages were grouped based on their oligomeric state and used to create
two ab initio 3D models. The 3D hexamer map was refined to a 3.08Å resolution using a total of
282,172 particles and C6 symmetry (Figure 8B & 8D). Due to an orientation basis of the
septamer complex, additional frames were collected to balance 2D views. These micrographs
were combined with the initial data set for a total of 6316 images. 540,617 additional particles
were picked, then all 1,217,696 particles were classed. Septamer classes were then classed two
additional times and selected to reduce orientation bias. The 3D septamer map was then refined
to a 3.39Å resolution using only 75,680 particles and C7 symmetry (Figure 8C & 8E).
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3.3.2 Expectantly, CPXV M2 interaction with hB7.2 parallels hB7.1
interaction and is validated using low-resolution X-ray scatter
CPXV M2 interaction with hB7.2 was assessed in the same manner as hB7.1 (Figure 9
and Table 1). 2197 micrographs were collected, 2045 of which were used to identify 293,790
particles. 2D class averages generated from the grouping of these particles also demonstrate the
formation of M2 hexamer and septamer rings capable of engaging one hB7.2 per subunit (Figure
9A). Class averages were grouped into hexamer or septamer selections and used to create two ab
initio 3D models. The 3D hexamer map was refined to a 3.98Å using a total of 71,427 particles
and C6 symmetry (Figure 9B & 9D). The 3D septamer map was refined to 4.10Å resolution
using a total of 51,688 particles and C7 symmetry (Figure 9C & 9E). In a complementary
technique, small-angle X-ray scatter (SAXS) analysis of CPXV M2 in complex with hB7.2 was
conducted (Figure 10). Analysis of CPXV M2 in complex with hB7.2 via PRIMUS102 gives a
gyration radius (Rg) of 72.72Å, a max diameter (DMax) of 243.0Å, and a molecular weight of
585kD (Figure 10A). DAMMIF103 was then used to generate 10 ab initio models of the complex
constrained to P6 or P7 symmetry which were then averaged using DAMAVER (Figure 10B &
10C). Hexamer modeling resulted in a mean NSD of 0.751 and a x2 of 0.381. Septamer modeling
resulted in a mean NSD of 0.679 and a x2 of 0.378. Envelopes of both SAXS models correlate
with corresponding cryo-EM maps providing additional evidence for the both hexameric and
septameric assembly of the M2:hB7.2 complex.

3.3.3 CPXV M2 directly completes with CTLA-4 for binding hB7.1 and hB7.2
via interaction with overlapping interface
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In addition to confirming two dominant oligomeric states of CPXV M2, cryo-EM
analysis also determined that each monomeric unit of the CPXV M2 ring binds one B7 molecule.
Additionally, M2 binds hB7.1 and hB7.2 using the same molecular determinants as the CTLA4/CD28 (Figure 11 & 12). The 3.08 Å resolution cryo-EM map was used to de novo model
CPXV M2 (Figure 11A and Table 2). CPXV M2 was threaded to structures of known PIE
proteins using PHYRE2

45,70

. Each threaded model was then docked into the cryo-EM map to

form the hexamer ring until the best fit was acquired using M2 threaded to VACV A41 (PDB ID:
2VGA). The crystal structure for hB7.1 ectodomain (PDB ID: 1DR9) was docked into the cryoEM map until the best fit was achieved. Due to the low resolution of the c-terminal region of
B7.1, only the receptor binding n-terminal domain was modeled and refined. This lower
resolution is likely due to motion of the c-terminus when bound by CPXV M2. The model was
then refined using PHENIX software (Table 2).109 The refined hexamer model show hB7.1
monomers to interact with individual subunits of the inner M2 ring in an orientation that
occludes the CTLA-4 binding site (Figure 11C-11E & Figure 12)35. Specifically, hB7.1
residues Tyr31, Met38, Thr41, Met43, Val83, Leu85, Ala91, Phe92, and Leu97 form direct
contacts with CTLA-435. M2 forms hydrogen bonds with atoms in residues Phe92, Lys93,
Arg94, His96, Glu99, and Thr101. These interactions cause the protein surface containing
CTLA-4 interaction residues to face towards the CPXV M2 ring, with no accessibility available
to CTLA-4 or CD28.
The refined M2 monomer was then used to build the remaining models (Figure 11B,
11F, and 11G). In the same manner, the crystal structure for the receptor binding domain of
hB7.2 (PDB ID: 1ncn) was docked into the hexamer CPXV M2:hB7.2 cryo EM map and refined
(Figure 11F). The CTLA-4/B7.2 interface is stabilized through hydrogen bonding and van der
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Waals contacts34. B7.2 residues Val29, Phe31, Gln33, Asn37, Leu38, Val39, Glu42, Tyr44,
Ser52, Ile86, His88, and Met95, participate in van der Waals contacts with CTLA-4, while
Asn37, Glu42, Lys49, and Arg97 participate in a series of potential hydrogen bonds34. Arg97 of
hB7.2 is also involved in an ionic interaction that acts to stabilize the CTLA-4/hB7.2 interface.
Each of the hB7.2 residues that interact with CTLA-4 lie on the front beta sheet of hB7.2 facing
toward CPXV M2 (Figure 11H–11J & Figure 12). Here, M2 forms close contacts with Phe31,
Gln84, His88, Met95, Ile96, Arg97, Gln100, and Asn102. Taken together, this data clearly
shows that CPXV M2 directly competes for binding to hB7.1 and hB7.2 by interacting with the
same protein surface containing the CTLA-4/CD28 binding interface.

3.3.4 CPXV M2 oligomerization drastically increases surface-molecule
interaction and is dependent upon intermolecular disulfides formed between
Cys25 of one subunit and Cys130 of the adjacent subunit.
CPXV M2 forms both the hexamer and septamer ring using intermolecular disulfide
linkages between Cys25 of one monomer and Cys130 of the adjacent monomer (Figure 13A &
13B). Mutation of either of these cysteines results in the formation of majoritively monomeric
CPXV M2 (Figure 13C & 13D). While the interactions between immobilized CPXV M2 and
soluble B7 ligands were analyzed, the reverse interaction represents a more physiologically
relevant scenario. We propose that the oligomerization of secreted M2 allows the viral protein to
use multimeric interaction (avidity) to prolong overall surface interaction with B7 expressing
cells and reduce diffusion (Figure 14). Using site specific biotinylation of B7-BirA ectodomains,
B7 molecules were c-terminally immobilized to binding surface and M2 flown over. When this
interaction is assessed, the apparent interaction half-life increases dramatically. This would
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suggest that the oligomerization of M2 serves to prolong overall surface interaction while
properties of the monomeric interaction allow competition with CD28 and CTLA-4. Explicitly, it
is entirely possible that mB7.1-mediated CTLA-4/CD28 signaling still occurs while CPXV M2
remains engaged with cell surface. The rate at which CPXV M2 unbinds mB7.1 molecules
potentially allows for coreceptor engagement even with the viral protein present and active.

3.4 Material and Methods
Protein expression, production, purification and biotinylation. The cDNA for M2 (CPXV040
ORF; GenBank: AGZ00972.1) was PCR amplified from CPXVBR-infected Vero cells and cloned
in the mammalian expression vector pFM1.286 with a 6His tag fused in frame at the C-terminus.
M2 protein was purified from supernatant of pFM1.2-M2 transfected Expi293F cells 72 h post
transfection using nickel agarose beads (Goldbio) followed by size-exclusion chromatography on
a HiLoaD 26/60 Superdex 200pg column (GE Healthcare). The cDNA for murine B7.1 and B7.2
was cloned from the pMSCV- and pMXs-based83 retroviral expression vectors used in previous
studies91 to encompass ectodomain void of transmembrane region and endogenous signal
sequence. cDNA was then PCR amplified and cloned into the mammalian expression vector
pFM1.286 with a 6His tag fused in frame at the C-terminus. Protein purification proceeded as
described above. Human B7.1 (NM_005191.4) and B7.2 (NM_175862.5) cDNA was generated
via IDT gene blocks optimized for mammalian expression. Genes were ligated into pFM1.2
vectors using Gibson Assembly92 reagents (NEB) before 293F transfection. Protein was
subsequently purified as described above.
Native-PAGE
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M2 protein was analyzed using Invitrogen Native-PAGE system. Samples were diluted with
native running buffer with no denaturant present. Sample was then run on a Invitrogen 4-16%
Bis-Tris Native-PAGE gel for 4 hours at 90V. Gels were stained using Coomassie blue R-250
dye before analysis.
SDS-PAGE
M2 protein was analyzed using Invitrogen Nu-PAGE system. Samples were diluted with LDS
sample buffer with or without 5% β-ME present. Sample was then run on an Invitrogen 4-12%
Bis-Tris NuPAGE gel for 90 minutes at 125V. Gels were stained using Coomassie blue R-250
dye before analysis.
SEC-MALS
M2 protein proteins were loaded onto a size exclusion chromatography column in sizing buffer
(150 mM NaCl, 20 mM HEPES pH 7.4, 0.01% NaN3) in series with a Dawn HELEOS-II 18angle light scattering detector (Wyatt), Optilab rEX refractive index monitor (Wyatt), and
photodiode array detector 996 (Waters). The light scattering, refractive index change, and UV
light absorbance were measured, and the molecular weight of the eluted protein was calculated
using the Astra V macromolecular characterization software package (Wyatt).
Surface Plasmon Resonance
SPR binding experiments were performed on a Biacore T200 system (GE Healthcare) to measure
the kinetics and affinity of B7.1/2 to CPXV M2. Experiments were performed at 30 µl/min and
25°C using HBS-P (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% v/v Surfactant P20) as
running buffer. M2 was immobilized onto a CM5 sensor chip (GE Healthcare) using standard
amine coupling chemistry. Recombinant B7 molecules was injected over a range of
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concentrations (0.01µM to 400µM: range for all four experiments) for 600s, followed by a 600s
dissociation period. As a negative control, CPXV C8L (a non-binding PIE protein) was
immobilized to flow cell 1 and signal was subtracted from CPXV M2 response. Real-time data
were analyzed using BIAevaluation 3.1 (GE Healthcare). For the equal affinity binding sites
model, kinetic profiles and steady-state equilibrium concentration, curves were fitted using a
global 1:1 binding model. Negative stain-EM
~0.4µM M2 was loaded onto glow discharged formvar-/-carbon-coated copper (Cu) grids.
Samples were then suspended for ~5 minutes before being coated in dH2O for 30s. 1% aqueous
Uranyl Acetate was then used to stain protein grids with excess liquid wicked off using
Whatman paper. Grid was allowed to dry for 30min prior to viewing on EM scope. Samples
were viewed on a JEOL 1200EX transmission electron microscope (JEOL USA, Peabody, MA)
equipped with an AMT 8 megapixel digital camera (Advanced Microscopy Techniques,
Woburn, MA).
HT-SAXS
SAXS data was collected at the ALS-SIBYLS beamline 12.3.199,100,101,97. Unbound M2 protein
samples and samples with M2 in complex with hB7.2 were shipped to Berkely for HT-SAX
analysis. 32 frames were collected at 3 concentrations (96 total): 0.75mg/mL, 1.5 mg/mL, and 3 mg/mL.
Data was analyzed using ATSAS suite. Specifically, PRIMUS102 was used to determine average
gyration radius , max diameter, and molecular weight. Data was then modeled in DAMMIF103
and DAMAVER104 to produce reported bead profiles.
Cryo-EM Analysis
CPXV M2 was incubated in molar excess with respective B7 ligand. Samples were flash cooled
on carbon EM grids in liquid ethane using an FEI Vitrobot (ThermoFisher). Movies of the
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samples were recorded with the software EPU (Thermo Fisher) using a K2 Summit electron
detector (Gatan) mounted on a Bioquantum 968 GIF Energy Filter (Gatan) attached to a Titan
Krios microscope operating at 300 keV with an electron dose of 1.67 e−/Å2 or 1.54 e−/Å2 and a
magnification of 125,000x. The movies (30 frames, 300 ms exposure per frame) were corrected
for beam-induced motion using MotionCor2110. Contrast transfer function parameters of the
electron micrographs were estimated using Gctf111 in RELION106,107. Particles were auto-picked,
and underwent reference-free 2D classification, ab initio 3D reconstruction, and 3D refinement
in RELION. Additional information regarding the number of images and particles is listed in
Table1. Structural visualization of the 3D reconstructions was performed using the programs
Chimera112 and PyMOL113.
Model Refinement
CPXV M2 was threaded to structures of known PIE proteins using PHYRE2

45,70

. Each threaded model was then

docked into the cryo-EM map to form the hexamer ring until the best fit was acquired using M2 threaded to VACV
A41 (PDB ID: 2VGA). Crystal structures for hB7.1 (PDB ID: 1DR9) and hB7.1 (PDB ID: 1NCN) were docked into
the

density map until the best fit was achieved. The map was manually inspected before model

refinement in PHENIX114–116. Model underwent several rounds of refinement with statistics
reported in Table 2.
Avidity Experiments (BLI)
Physiologically relevant binding of CPXV M2 and B7 ligands was monitored in real-time at
25°C using an Octet-Red96 device (Pall ForteBio). B7 ectodomain-encoding gene blocks were
designed to contain c-terminal BirA tags and molecules were coexpressed with BirA for site
specific biotinylation. Biotinylated-B7 molecules were loaded onto streptavidin biosensors
(ForteBio) until saturation, typically 0.1µM for 180s, in 10 mM HEPES (pH 7.4), 150 mM NaCl,
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3 mM EDTA, and 0.005% P20 surfactant. Loading was analyzed in real time. Biosensors were
then dipped into varying concentrations of M2 for 15min for association curves. Following the
association step, disassociation took place in buffer-only containing wells for 30 min. Curves
were analyzed using BiaEval3.
Antibodies and reagents. Antibodies to human B7.1 (clone L307.4), mouse B7.2 (clone GL1),
mouse B7.1 (clone 16-10A1) and isotype controls were obtained from BD Pharmingen or
eBioscience, while anti-human CD86 (clone BU63) and flag (M2) antibodies were from
Serotech and Sigma, respectively. The recombinant mouse and human CD28 and CTLA4 as well
as PD-L1, all fused with Fc of human IgG1 at the C-terminus except human PD-L1 fused with
Fc of mouse IgG1, were purchased from Sino Biological Inc. In flow cytometric analysis,
stainings of these Fc-fusions were visualized by Alexa Fluor488 or Alexa Fluor647 labeled goat
anti-human IgG or goat anti-mouse IgG (Life Tech) while biotinylated M2 and controls were
detected by PE-Streptavidin (BD Pharmingen) using a BD FACS Calibur.
Ex vivo T cell activation, proliferation and IL-2 assays. Mouse splenic T cells from C57BL/6
mice were enriched by passing through a nylon wool column88. Enriched T cells were cultured at
2.5-5x105 cells/well with 0.5-1x105 cells/well MEF-mB7.1 or MEF-mB7.2 or CH27 cells in a
96-well plate pre-coated with 50 µl of 0.5µg/ml hamster anti-mouse CD3ε (clone 500A2, BD
Pharmingen). Purified recombinant M2 or unrelated PIE control, mouse CTLA4-Fc, anti-mouse
B7.2 (GL1) or isotype IgG were added in culture at the concentration specified. After incubation
at 37 °C for 48 h, IL-2 in culture supernatant was assessed by ELISA in triplicates using antimouse IL-2 antibody pair (JES6-1A12 and JES6-5H4, BioLegend) for capture and detection. For
proliferation assays, the enriched splenic T cells were stained with 10µM CFSE (Life Tech) at
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37 °C for 15min before co-culture with the MEF-mB7.2 cells in the presence or absence of
indicated antagonists. CFSE-dilution in the CD3+CD4+ population was analysed 3 days later by
flow cytometry.
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3.5 Figures and Tables

Illustration of mammalian expression of recombinant protein: cDNA is cloned into pFM1.2
expression vector. DNA is mixed with lipofectant reagent and subsequently used to transfect
Exp293F cells. Protein is secreted via endogenous signal sequence. Cells are pelleted via
centrifugation and recombinant protein-containing supernatant is collection. Recombinant
protein is then purified supernatant.
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FPLC traces of recombinant human and mouse B7.1&2 and CPXV M2 show robust, clean
expression: Following mammalian expression and Ni2+-column chromatography, recombinant
proteins were further purified using size exclusion chromatography. FPLC traces show distinct
bell-shaped peaks indicative of good purification.
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CPXV M2 forms disulfide linked quaternary structure that constitutively exist in two
oligomeric states: A) Redcing SDS-PAGE analysis of CPXV M2 shows reduction of oligomer
in the presence of reducing agent. β –ME is indicated by + or -. B) SEC-MALS analysis of
CPXV M2 produces a molecular weight of 194kD signifying oligomeric organization. C)
Native-PAGE analysis of CPXV M2 displays two bands indicative of at least two constitutive
oligomeric states by CPXV M2.
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Negative stain-EM, SAXS, and native-MS support formation of ringed M2 oligomers likely
existing as hexmaers and septamers: A) Negative stain electron microscopy (EM) of CPXV
M2 shows the formation of ringed structures. Average diameter of CPXV M2 ringed oligomers
is 11.4nm. B) Native mass spectroscopy spectra of CPXV M2. Here CPXV M2 was expressed
with N › Q mutations, to eliminate glycan sites and reduce heterogeneity, and then subjected to
Native-MS analysis (CPXVM2_GlyMut). Eight individual peaks were analyzed for information
on M2’s native state. CPXVM2_GlyMut was determined to exist in two states with molecular
weights of 148kD and 172.5kD. With an expected monomeric of 24.5kD, this data provides
further evidence for the formation of a hexameric species (148kD / 24kD = 6.04) and a septamer
species (172.5kD / 24.5kD = 7.04) by CPXV M2. Cyan hexamers denote peaks corresponding to
hexamer species. Purple septamers denote peaks corresponding to septamer specieis. C) X-Ray
scatter (SAXS) profile of CPXV M2 resembles profiles of other known ringed proteins96–98.
Profile was generated by averaging individual profiles from 32 frames at 3 concentrations (96
total). Analysis via PRIMUS102 gives a gyration radius (Rg) of 50.85Å, a max diameter (DMax) of
159.6Å, and a molecular weight of 198kD. All consistent with negative stain-EM and SECMALS data. D) Using P6 symmetry in DAMMIF and DAMAVER103 a hexamer model envelope
of CPXV M2 was generated from the averaged intensity profile. Hexamer modeling resulted in a
mean 0.329 and a x2 of 0.438. E) Using P7 symmetry in DAMMIF and DAMAVER a septamer
model envelope of CPXV M2 was generated from the same averaged intensity profile. Septamer
modeling resulted in a mean NSD of 0.433 and a x2 of 0.488.
61

SPR illustration depicting monotypic M2/B7 binding analysis: For monomeric interaction
analysis, CPXV M2 was immobilized to sensor chip surface. B7 ligand was flown over chip at
varying concentrations. Response curves were analyzed.
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CPXV M2 binds B7.1 and B7.2 with similar affinities but distinct kinetics. Surface plasmon
resonance (SPR) was used to asses CPXV M2 interaction with human and murine B7.1 and
B7.2. The 1:1 Langmuir model was used to kinetically assess binding curves. Black curves
represent raw data while red curves represent kinetic fits. CPXV M2 demonstrates similar
affinities and kinetics between hB7.1 and hB7.2. However, while CPXV M2 has slightly higher
affinity for mB7.1, kinetic analysis reveals a much quicker off-rate and significantly shorter halflife when compared to mB7.2 interaction A) SPR analysis of CPXV M2 interaction with hB7.1.
hB7.1 samples, at concentrations serially diluted from 20µM to 0.010µM, were flown over
immobilized CPXV M2. B) hB7.2 samples, at concentrations serially diluted from 40µM to
0.020µM, were flown over immobilized CPXV M2. C) mB7.1 samples, at concentrations
serially diluted from 250µM to 0.977µM, were flown over immobilized CPXV M2. D) mB7.2
samples, at concentrations serially diluted from 400µM to 1.56µM, were flown over immobilized
CPXV M2.
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The 2:1 heterogeneous ligand model better fits SPR binding data, likely due to multiple M2
states: Here the 2:1 heterogeneous ligand model was used to fir curves. This model takes into
account two ligands (hexamer, septamer) binding the same analyte (B7s). The fit is clearly better
as indicated by better chi2 values. Elucidating which state binds with which affinity has not yet
been possible. A) SPR analysis of CPXV M2 interaction with hB7.1. hB7.1 samples, at
concentrations serially diluted from 20µM to 0.010µM, were flown over immobilized CPXV
M2. B) hB7.2 samples, at concentrations serially diluted from 40µM to 0.020µM, were flown
over immobilized CPXV M2. C) mB7.1 samples, at concentrations serially diluted from 250µM
to 0.977µM, were flown over immobilized CPXV M2. D) mB7.2 samples, at concentrations
serially diluted from 400µM to 1.56µM, were flown over immobilized CPXV M2.
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Cryo-EM analysis of CPXV M2 in complex with hB7.1 confirm existence of M2 hexamers
and septamers, with each subunit capable of binding one B7 molecule: A) 2D class averages
of CPXV M2 in complex with hB7.1 show the formation of hexamer and septamer oligomeric
states. Using RELION software, individual particles were grouped into 200 classes and averaged
based on their structural characteristics and view orientation. Examples of hexamer and septamer
2D classes are present. B) FSC plot for septamer 3D reconstruction with resolution at FSC=0.5
and FSC=0.143 highlighted. C) FSC plot for hexamer 3D reconstruction with resolution at
FSC=0.5 and FSC=0.143 highlighted. D & E) Top, side, and bottom views of 3D envelopes of
CPXV M2 in complex with hB7.1 generated for both the hexamer (D) and septamer (E)
complexes. Maps are colored by local resolution indicated by rainbow bar.
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Cryo-EM analysis of CPXV M2 in complex with hB7.2 confirm existence of M2 hexamers
and septamers, with each subunit capable of binding one B7 molecule: A) 2D class averages
of CPXV M2 in complex with hB7.2 show the formation of hexamer and septamer oligomeric
states. Using RELION software, individual particles were grouped into 200 classes and averaged
based on their structural characteristics and view orientation. Examples of hexamer and septamer
2D classes are present. B) FSC plot for septamer 3D reconstruction with resolution at FSC=0.5
and FSC=0.143 highlighted. C) FSC plot for hexamer 3D reconstruction with resolution at
FSC=0.5 and FSC=0.143 highlighted. D & E) Top, side, and bottom views of 3D envelopes of
CPXV M2 in complex with hB7.1 generated for both the hexamer (D) and septamer (E)
complexes. Maps are colored by local resolution.
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SAXS analysis of CPXV M2 in complex with B7.2 corroborates cryo-EM data: A) X-Ray
scatter profile of CPXV M2 in complex with human B7-2. Profile was generated by averaging
individual profiles from 32 frames at 3 concentrations (96 total). Analysis via PRIMUS gives a
gyration radius (Rg) of 72.72Å, a max diameter (DMax) of 243.0Å, and a molecular weight of
585kD. Kratky plot is shown in top right corner. (B) Using P6 symmetry in DAMMIF and
DAMAVER a hexamer model envelope of the CPXV M2:hB7-2 complex was generated from
the averaged intensity profile. Hexamer modeling resulted in a mean NSD of 0.751 and a x2 of
0.381. The generated SAXS model strongly resembles the hexameric cryo-EM 3D model. (C)
Using P7 symmetry in DAMMIF and DAMAVER a septamer model envelope of CPXV M2 was
generated from the same averaged intensity profile. Septamer modeling resulted in a mean NSD
of 0.679 and a x2 of 0.378. Like the hexameric SAXS and cryo-EM model, the generated
septamer model strongly resembles the septameric cryo-EM 3D model.
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CPXV M2-B7 binding interfaces overlap with interface of CTLA-4, confirming direct
competition mechanism of action for hB7.1 and hB7.2 A) Atomic model for CPXV M2/
hB7.1 hexamer B) Atomic model for CPXV M2/ hB7.1 septamer C) Ribbon model of
monomeric interaction D) Surface representation of M2 and B7.1 with contact sites colored
cyan. CTLA-4 contacts are mapped in yellow. Overlapping residues are colored green E) Ribbon
illustration hB7.1 with contact residues represented as sticks and color coated as described in (D)
F) Atomic model for CPXV M2/ hB7.2 hexamer G) Atomic model for CPXV M2/ hB7.2
septamer H) Atomic Ribbon models of monomeric interaction I) Surface representation of M2
and B7.1 with contact sites colored cyan. CTLA-4 contacts are mapped in yellow. Overlapping
residues are colored green J) Ribbon illustration hB7.2 with contact residues represented as
sticks and color coated as described in (I)
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B7s alignment showing M2 contact sites: Magenta blocks depict M2:hB7.1 contacts. Red
blocks show M2:hB7.2 contacts. Cyan residues are overlaps between hB7.1 & 2. Van der waals
contact number is shown for each hB7.1 or 2 contact on their respective sequence. CTLA-4
contacts are identified with yellow circles below.
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M2 residues Cys25 and Cys130 are residues responsible for oligomer- forming
intermolecular disulfide bonds: Cys25 on one monomeric unit of M2 forms a dilsulfide bond
with Cys130 on an adjacent subunit. Mutating either of these Cys residues results in
constitutively monomeric CPXV M2. A) Top view of CPXV M2 hexamer model shows disulfide
bonds between each subunit. Bonds are colored yellow with black arrows highlighting location.
B) Top view of CPXV M2 septamer model shows disulfide bonds between each subunit. Bonds
are colored yellow with black arrows highlighting location. C) SDS-PAGE analysis shows the
loss of higher oligomeric weight species when Cys25 or Cys160 is mutated to Ser with or
without the presence of reducing agent (𝞫ME). A negative control mutation of Cys160 does not
ablate oligomer formation.
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Avidity studies show long-lasting interactions between CPXV M2 and c-terminally
immobilized B7s: Surface plasmon resonance (SPR) was used to analyze the potential
contribution of avidity (overall affinity) in CPXV M2 interaction with human and mouse B7
ligands. Using BirA mediated c-terminal biotinylation, the extracellular-domain of the respective
B7 ligand was immobilized to the sensor chip surface in a manner resembling B7 expression on
cellular surfaces. (A) M2 was flown over immobilized hB7.1 at serially diluted concentrations
ranging from 0.0156-1µM, and response was recorded. (B) M2 was flown over immobilized
hB7.2 at serially diluted concentrations ranging from 0.0156-1µM, and response was recorded.
(C) M2 was flown over immobilized mB7.1 at serially diluted concentrations ranging from
0.156-5µM, and response was recorded. (D) M2 was flown over immobilized mB7.1 at serially
diluted concentrations ranging from 0.156-5µM, and response was recorded. To determine the
overall, apparent affinity, all binding curves were analyzed kinetically using a 1:1 binding model.
Apparent half-lives along with kinetic and steady state disassociation constants are reported for
each interaction.
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Summary of Cryo-EM data collection and processing. Related to figures 8 and 9.
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Cryo-EM model building and refinement statistics, Related to figures 11 & 12
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Chapter 4: Conservation of oligomerization
and species specific B7 binding by poxvirus
M2 analogs
The research within this chapter consists of data that are published in Viruses and data that is in
preparation for submission to a virological journal
Nelson C, Epperson M, Singh S, Elliott J, Fremont D. Structural Conservation and Functional
Diversity of the Poxvirus Immune Evasion (PIE) Domain Superfamily. Viruses.
2015;7(9):4878-4898. doi:10.3390/v7092848
Christopher Nelson collected and processed the genomic data. The figures were constructed by
Christopher Nelson and Megan Epperson. Sukrit Singh and I helped with data analysis, literature
review, and data discussions. Christopher Nelson, Megan Epperson and Daved Fremont wrote
the manuscript.
Jabari I. Elliott, Xiaoli Wang, Christopher A. Nelson, Wayne M. Yokoyama, Daved H. Fremont.
Ability to sabotage T cell costimulation is conserved in poxvirus M2 analogs.
My contribution to this work included executing binding studies, cryo-EM data processing, flow
cytometry experiments, , and mutagenesis.
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4.1 CPXV M2 comprises PIE core domain and M2 analogs
are encoded by at least 18 other poxviruses.
Conservation of certain proteins or protein characteristics usually implies a significance
for that element, as evolution has driven its retention across multiple species. This is evident in
poxviruses as we’ve previously identified over 150 potential PIE proteins, expressed by varying
poxviruses45. Using structure based alinements, these proteins are all predicted to assemble the
conserved PIE core domain. Additionally, 19 of the examined poxviruses, including CPXV BR,
encode a sequence predicted M2 analog. The conservation of both the PIE fold and M2 protein
speaks to their presumed importance in successful viral immune evasion. Furthermore, CPXV
M2 uses unordered, coil decorations to engage B7 molecules and stabilize CPXV M2
oligomerization via aromatic ring stacking across subunits117.

4.1.1 CPXV M2 adopts core PIE domain with decorations responsible for
oligomerization and B7 interaction
The core structure of the PIE domain consists of a compact globular β-sandwich formed
from two nearly parallel β-sheets. As predicted, CPXV M2 adopts the signature PIE domain ßsheet fold. Using the atomic model derived from high resolution cryo-EM data, M2 was
physically aligned to a structure-based computationally-generated PIE domain model along with
known structures of solved PIE proteins (Figure 1). Typically, PIE parallel β-sheets are
connected by loops that frequently contain short β-strands and α-helices. Noticeably, M2 βstrand connections contain a significant volume of “random” coil. Interestingly, these coil
regions seem important for oligomerization. Explicitly, β-strands 10 and 1 are considerably
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shorter than in other PIEs. This allows the coiled, β-strand connection from β10 to β11 to run
perpendicular to the β-sandwich. Along this strand, stacking interactions are observed between
aromatic residues of one monomer and an N-linked glycan of the adjacent subunit.
Synergistically with disulfide linkages, these interactions potentially stabilize oligomer
formation. Consistent with PIE proteins CPXV 203 (PDB ID: 4HKJ) and ECTV CrmD, the
connection from β7 to β9 adopts the formation of a conservation-transient 8th β-strand to create
an interface containing residues responsible for interaction with B7 ligands. As with other PIE
proteins, M2’s non-conserved regions (dark blue) are necessary for immunomodulatory function.
Additionally, the loss of PIE-conserved disulfide bonds “A” and “C” leads to unpaired cysteine
residues at position 25, 130, and 149. As discussed earlier, residues 25 and 130 are responsible
for intermolecular disulfide bonds between M2 subunits. These results show that non-conserved
“decorations” arranged onto the conserved PIE core domain are necessary for CPXV M2 to carry
out its immunomodulatory function. This is consistently with the larger PIE domain theory
described earlier. Additionally, conservation based sequence analysis shows many M2 analogs
possibly conserve B7 binding and oligomerization.

4.1.2 M2 protein ORFs are conserved across the poxvirus family
Validating its significant to viral immune evasion, M2 was found in almost all
orthopoxviruses examined, along with leporipoxvirus, yoka poxvirus, and cotia poxvirus (Table
1). While some studies suggest VACV WR M2 serves intracellular roles118–120, it appears likely
the primary function of M2 remains unreported. Interestingly, Yoka poxvirus contains a protein
that appears to be a member of the M2 family (~57% to cowpox M2) and a second ORF with
slightly less similarity to M2 (~34% identity). Presumably the two proteins, being in the same
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virus, serve different functions; therefore, we term the second protein as M2-like. Yaba monkey
tumor virus and deerpox virus also encode M2-like proteins in addition to a predicted M2 family
member. The conservation of M2 encoding ORFs, across numerous poxvirus genomes, suggests
its importance in poxvirus infection.

4.2 M2 analogs from YKV, MYXV, and VACV WR also
form high molecular weight oligomers.
Because M2 is a highly-conserved protein in the poxvirus family, we wanted to
determine whether functional roles observed by CPXV M2 were conserved as well. Following a
quick sequence alignment analysis of predicted M2 proteins, three poxvirus M2s were chosen for
additional study: VACV WR M2 (M2L), MYXV M2, and YKV M2. Experiments following
their subsequent expression divulge information consistent with conservation of oligomer
formation. However, while oligomer formation is conserved amongst the M2 family, further
investigation implies distinct differences in constitutive states (multiple vs single state) and
quaternary arrangement (# of subunits).

4.2.1 Biophysical analysis of poxvirus M2 analogs reveal conservation of
oligomerization
M2’s from three poxviruses were recombinantly expressed to assess plausible
conservation

of

B7

binding

function.

Analogs

were

selected

based

on

their

similarity/dissimilarity with CPXV M2, in an effort to assess a broad sequence range within the
M2 family (Figure 3A). Specifically, VACV WR M2 (M2L) was selected because of its high
similarity (95%) with mature CPXV M2 post signal peptide cleavage. Contrastingly, YKV M2
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(YK_170) and MYXV M2 (mau_154) share 57% and 55% similarity respectively, and represent
the most distally related M2s from CPXV M2. M2 analogs, expressed and purified in the same
manner as CPXV M2, were analyzed via size exclusion chromatography coupled multi-angle
light scatter (SEC-MALS) (Figure3B). As a reminder, CPXV M2 analysis results in a molecular
weight of 194kD ± 0.3. VACV WR M2 analysis resulted in an average molecular weight of
205kD ± 0.4. MYXV M2 constitutively exists with an average molecular weight of 110kD ± 0.6,
smaller than that seen for CPXV and VACV WR M2s. Lastly, a molecular weight of 397kD ±
0.1 is obtained following YKV M2 analysis and suggest the formation of a significantly larger
oligomeric state as compared to the other M2 analogs. Seemingly, all M2 analogs analyzed share
the ability to form high molecular weight oligomers.

4.2.2 Native-PAGE analysis of M2 analogs demonstrate differences in protein
state compositions
Like with CPXV M2, native-PAGE analysis was used to probe constitutive states for M2
analogs (Figure 4A). Logically, the M2 analog sharing the most similarity with CPXV M2,
VACV WR M2, also likely forms hexameric and septameric states. This is evident by two bands
parallel to those of CPXV M2. MYXV M2, the smallest analog by SEC-MALS calculated
molecular weight, runs as one concise band, slightly lower than CPXV and VACV WR M2
bands. The most confounding analysis is that of YKV M2. Correlative to SEC-MALS data, YKV
M2 consistently runs as a blurred band, significantly higher than all other M2 analogs. While
native-PAGE data cannot typically be used to report on the size of proteins/complexes, this data
correlates extremely well with what is seen by the absolute MW determination method, SECMALS (above). Lastly, SDS-PAGE analysis was used to confirm breakdown of oligomeric
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species into monomeric subunits (Figure 4B). Here samples were incubated at 95ºC in SDS
running buffer in the presence or absence of reducing agent. Samples were then run on a 4-12%
gradient gel. For CPXV and VACV WR M2s clear bands representing oligomer formation and
ß-ME-induced reduction to monomeric subunits are observed. Notably, regardless of reducing
agent presence, MYXV M2 runs a single low molecular weight band. This would suggest the
formation of a non-disulfide linked oligomer by MYXV M2 capable of reduction by SDS and
heat alone. However, YKV M2 only shows faint banding where monomeric identification is
predicted. While YKV M2 requires additional analysis, these data show that oligomerization of
monomeric subunits is conserved in M2 across poxvirus species.

4.3 M2 analogs conserve B7 binding function in a speciesspecific manner.
CPXV M2 shows strong surface staining of fibroblasts transfected with human B7.1
(hB7.1), human B7.2 (hB7.2, ), murine B7.1 (mB7.1), or murine B7.2 (mB7.2)91. Therefore, we
examined B7 ligand binding by the different M2 analogs. Surprisingly, M2s conserved B7
binding capability, but with species dependent specificity. This specificity directly affects
functionality, as only M2 analogs capable of compelling interaction with surface mB7.2 are
capable of blocking mB7.2-mediated T cell costimulation. Positive cell staining was confirmed
using recombinant proteins assessed via biophysical characterization. Here, it was also observed
that the preferential interaction seen between CPXV M2 and mB7.2, was consistent for both
YKV and MYXV M2 interaction with their species-respective ligands.
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4.3.1 M2 analogs bind surface of cells expressing B7.1 or B7.2 with some
species specificity
Flow cytometry was used to assess M2 analog interaction with cellular surfaces of mouse
embryonic fibroblasts (MEFs) transfected with either human or mouse B7.1 or B7.2. These
experiments revealed species-specific conservation of B7 binding amongst the M2 analogs
(Figure 5A). Explicitly, VACV WR M2L, strongly interacts with hB7.1, hB7.2, and mB7.1, but
didn’t bind mB7.2. As VACV M2 is the only M2 protein with any previously reported function,
it should be noted that VACV WR M2 possibly has dual/differing function. MYXV M2 robustly
stains surface of cells expressing human B7.1 or B7.2 to the level of CPXV M2, but is unable to
bind murine B7.1 or 2. This is of interest as the natural host for myxoma virus is a species of
American rabbit: S. Bachmani121. Oppositely, YKV M2 interacts strongly with cell surfaces
containing murine B7.1 or B7.2, but displays no affinity for surface human B7 counterparts.
Yokapox virus has no known natural host as it was isolated from mosquitos in Central African
Republic (1972)122. These findings support the notion of B7-binding conservation by M2
analogs, but with significant species specificity.

4.3.2 Only M2 analogs capable of interaction with murine B7.2 can block Tcell activation in vitro.
To test the functional implications of conserved B7 binding, M2 anaolgs were subjected
to T cell activation assays used earlier to assess CPXV M2’s role in costimulation suppression.
Again, in the presence of low anti-CD3ε, T cells were cocultured with mB7.2 expressing MEF
cells in the presence or absence of M2 analogs (Figure 5B). Like before, IL-2 production was
used as a measurable readout for T cell activation. As expected, the presence of CPXV M2 or
80

YKV M2, the only two analogs capable of robust MEF-mB7.2 interaction by FACS, leads to a
drastic suppression of IL-2 production by activated T cells. This suppression is comparable to
suppression observed when mB7.2 blocking antibody is present signifying strong mB7.2
blockade by both CPXV and YKV M2. Analogs incapable of noticeable interaction with cell
surface mB7.2, MYXV and VACV WR M2, show no effect on T cell costimulation, evident by
optimal IL-2 production. This data further supports conserved B7-specific immunomodulatory
function for the M2 PIE-protein family.

4.3.3 Resembling CPXV M2’s binding of mB7.2 vs mB7.1, YKV and MYXV
M2 analogs also display preferential B7.2 binding.
SPR was again used to investigate interaction strength between M2 analogs and their
respective B7 ligands. Like previous experiments, M2 analogs were immobilized to the CM5
chip surface using amine coupling. Species appropriate B7 ectodomains were flown over each
M2 analog and response signal was recorded (Figure 6). Consistent with flow cytometry data,
VACV WR M2 bound human and mouse B7.1 with kinetic disassociation concentrations of
0.296µM and 1.66µM and interaction half-lives of 102s and 65s respectively (Figure 6A & 6B).
The weakest interaction and shortest half-life observed for VACV WR M2 was with hB7.2
(KD,Kin = 4.20µM, t1/2 = 7.5s), contrasting what was observed with CPXV M2 (Figure 6C).
Again, VACV WR M2 is the only M2 with any previously reported function and may have
varying roles during viral infection. However, consistent with CPXV M2’s preferentiality of
B7.2 over B7.1, both MYXV M2 and YK M2 demonstrate increased interaction durability when
binding B7.2 in comparison to B7.1. Specifically, MYXV M2 binds hB7.2 with a significantly
higher affinity than hB7.1 (Figure 6D and Table1). The duration of this interaction is also
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noticeably longer. Similarly, YKV M2-mB7.2 interaction has a t1/2 of 182 seconds, but a 75s
half-life is overserved for mB7.1 interaction (Figure 6E & 6F). These results not only further
support M2 preference for B7.2 over B7.1, but also illustrates the distinction in the nuanced roles
of B7.1 and B7.2 during costimulation. All interactions are summarized in Table 2. Additionally,
curves for M2 analogs displaying possible formation of multiple oligomeric states were
reanalyzed using the 2:1 HL binding model. These results are summarized in Table 3.

4.4 Cryo-EM analysis of MYXV M2 in complex with human
B7.2 confirms varying M2 state compositions for the M2
protein family
Following biophysical characterization, M2 analogs were subjected to structural analysis
via Cryo-EM. While preliminary images showed ring formation by YKV M2 (data not shown),
only MYXV M2 in complex with hB7.2 produced data sufficient for map generation (Figure 7
and Table 4). Like CPXV M2, MYXV M2 was visualized using the FEI Titan Krios Cryo-TEM.
3617 micrographs were collected and analyzed using RELION software106,107. The automated
particle picker, Cryolo108 was used to pick 289,502 particles from images. 2D class averages
were then generated from sorting and overlaying the individual particles and revealed the
formation of pentamers by the myxoma virus protein (Figure 7A). As indicted by native-PAGE
analysis, MYXV M2 seems to exist in a single oligomeric state differing from CPXV M2. This is
particularly interesting as MYXV M2 lacks the M2-conserved cysteine residues that create
intermolecular disulfide bonds between CPXV M2 subunits, but retains the residues necessary
for aromatic ring stacking (Figure 2). This also correlates with what is seen by SDS-PAGE
analysis, as MYXV M2 runs as a monomeric band with or without reducing agent present. Using
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the 2D classes, a 3D map was generated and refined to 4.35Å resolution (Figure 7B and 7C).
While this resolution does not allow for de novo build of MYXV M2, it does provide crucial
information related to M2 family oligomerization and B7 engagement. Even at 4.35Å resolution
hB7.2 can be visualized in the same orientation seen in the CPXV M2: hB7.2 model. In totality,
these findings support oligomerization and B7 engagement by poxvirus M2s, but describe
intricate differences within the protein family.

4.5 Sequence conservation analysis can be used to determine
specific residues necessary for M2:B7 interaction.
Prior to solving the structure of CPXV M2, site-directed mutagenesis was used to gain
some residue specific information on M2/B7 interaction. Using what was known of analog
species specificity, M2 sequences were aligned and analyzed for specific residue changes. As
VACV WR M2 is the closest related M2, it served as a natural starting point. With only an eightresidue difference, but significant variation observed in B7.2 binding (mouse and human), it was
determined that one of the non-conserved residues were important for B7.2 interaction,
specifically mB7.2. Because both viral proteins only bind one species of B7 (mouse vs human),
YKV and MYXV M2 sequences were used to further assess these residues. Via process of
elimination, residues responsible for mB7.2 interaction were predicted and tested using
mutagenesis. As it turns out, two side-by-side mutations completely ablate mB7.2 binding by
CPXV M2. Importantly, this CPXV M2 mutant data concurs with what is seen structurally.

4.5.1 Conservation based mutagenesis results in ablated mB7 binding
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Using sequence analysis, in parallel with binding data and T cell activation experiments, I
determined which residues of CPXV M2 are critical for mB7.2 interaction (Figure 8). Sequence
alignment of CPXV M2, VACV WR M2 (M2L), MYXV M2, and YKV M2 was first analyzed
to identify residues conserved in murine B7.2 binding M2 analogs. As mentioned earlier, CPXV
M2 and VACV WR M2 share 95% sequence identity; however, VACV M2 failed to bind murine
B7.2 and block murine T cell activation. Based on this observation, I identified nine amino acids
that are different in VACV versus CPXV M2 (Figure 8A). Following further sequence
comparison with mB7.2-binding YKV M2, I mutated His145 and Lys146 in CPXV M2 and
tested for their significance in binding mB7.2 using SPR. Of note, while Lys146 in not conserved
in YKV M2, a positive arginine residue takes its place. Therefore, Lys146 was mutated to test
for any electrostatic contributions. Neither single mutation could arrest murine B7.2 binding
alone. However, when both mutations were introduced simultaneously, CPXV M2 H145A
K146L (CPXV M2Mut), mB7.2 interaction was ablated (Figure 8C). CPXV M2Mut can no longer
bind mB7.2, but retains hB7.2 binding ability, albeit with much faster kinetics (Figure 8B &
8C). Correlative with binding data, no reduction in IL-2 production is seen when CPXV M2Mut is
present during T cell activation assays (Figure 8D). Of note, CPXV M2 His145 is conserved in
MYXV M2 which does not interact with murine B7.2. Therefore, this position was predicted to
be significant for general B7.2 binding. Notably, cryo-EM modeling implicates CPXV M2
His145 in hydrogen bond formation with hB7.2 residues (Figure 2).

4.6 Material and Methods
Protein expression, production and purification.
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DNA for all M2 analogs was generated via IDT gene blocks optimized for mammalian
expression (MK340973.1, MYXV). Genes were ligated into pFM1.2 vectors using Gibson
Assembly92 reagents (NEB) before 293F transfection. M2 protein analogs were purified from
supernatant of pFM1.2-M2 transfected Expi293F cells 72 h post transfection using nickel
agarose beads (Goldbio) followed by size-exclusion chromatography on a HiLoaD 26/60
Superdex 200pg column (GE Healthcare).
Native-PAGE
M2 protein analogs were analyzed using Invitrogen Native-PAGE system. Samples were diluted
with native running buffer with no denaturant present. Sample was then run on a Invitrogen 416% Bis-Tris Native-PAGE gel for 4 hours at 90V. Gels were stained using Coomassie blue R250 dye before analysis.
SDS-PAGE
M2 protein analogs were analyzed using Invitrogen Nu-PAGE system. Samples were diluted
with LDS sample buffer with or without 5% β-ME present. Sample was then run on an
Invitrogen 4-12% Bis-Tris NuPAGE gel for 90 minutes at 125V. Gels were stained using
Coomassie blue R-250 dye before analysis.
SEC-MALS
M2 protein analogs were loaded onto a size exclusion chromatography column in sizing buffer
(150 mM NaCl, 20 mM HEPES pH 7.4, 0.01% NaN3) in series with a Dawn HELEOS-II 18angle light scattering detector (Wyatt), Optilab rEX refractive index monitor (Wyatt), and
photodiode array detector 996 (Waters). The light scattering, refractive index change, and UV
light absorbance were measured, and the molecular weight of the eluted protein was calculated
using the Astra V macromolecular characterization software package (Wyatt).
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Surface Plasmon Resonance
SPR binding experiments were performed on a Biacore T200 system (GE Healthcare) to measure
the kinetics and affinity of B7.1/2 to CPXV M2. Experiments were performed at 30 µl/min and
25°C using HBS-P (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% v/v Surfactant P20) as
running buffer. M2 analogs were immobilized onto a CM5 sensor chip (GE Healthcare) using
standard amine coupling chemistry. Respective recombinant B7 molecules were injected over a range of
concentrations (0.01µM to 400µM: range for all experiments) for 600s, followed by a 600s
dissociation period (YKV M2 dissociation period:1200s). As a negative control, CPXV C8L (a nonbinding PIE protein) was immobilized to flow cell 1 and signal was subtracted from M2 analog
response. Real-time data were analyzed using BIAevaluation 3.1 (GE Healthcare). For the equal
affinity binding sites model, kinetic profiles and steady-state equilibrium concentration, curves
were fitted using a global 1:1 binding model.
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4.7 Figures and Tables

CPXV M2 conserves core PIE domain with decorations responsible for B7-binding
function and oligomerization: Strands in the β-sandwich core domain (cyan) are numbered the
same as structures in Chapter 1 Figure 4, to aid comparison. The decorations unique to M2
structure are colored dark blue. Cysteines are show in yellow with black stars depicting cysteine
pair involved in intermolecular disulfide. The conserved disulfide bonds are labeled in red (B, D,
F). hB7.1igand contact regions are annotated with magenta sticks. hB7.2 contact regions are
shown with red sticks Residues involved in aromatic packing at oligomer interface are shown in
lime green.

87

Sequence alignment of M2 analogs: Secondary structure is mapped above sequences and colorcoded to match (Figure 1). Cysteines are blocked in yellow. Magenta circles identify residues
involved in hB7.1 binding while red triangles depict hB7.2 contact residues. Cyan diamonds
show overlap between hB7.1 and hB7.2 contacts. Green diamonds show residues implicated in
oligomer formation. Disulfide pairs are denoted with red letter above cysteines. Black stars
indicate cysteine residues involved in intermolecular disulfide bonds.
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SEC-MALS confirm oligomer formation by M2 analogs, but with wide range of molecular
weights A) Phyleogenetic tree depicting protein sequence similarity between select poxvirus M2
analogs123. The stalk distance values represent the number of residue substitutions as a
proportion of the length of the alignment. In respect to CPXV M2, VACV M2L, MYXV M2,
and YKV M2 share 95%, 55%, and 57% similarity respectively. B) Analysis via size exclusion
chromatography coupled multi-angle light scatter (SEC-MALS) of CPXV M2 results in a
molecular weight of 194kD ± 0.3. MW trace (grey), fit (red), and UV trace (blue) depicted. E)
Analysis via size exclusion chromatography coupled multi-angle light scatter (SEC-MALS) of
VACV M2L results in a molecular weight of 205kD ± 0.4, also suggesting the formation of large
oligomer states. F) Analysis via size exclusion chromatography coupled multi-angle light scatter
(SEC-MALS) of MYXV M2 results in a molecular weight of 110kD ± 0.6 suggesting the
formation of smaller oligomer states. G) Analysis via size exclusion chromatography coupled
multi-angle light scatter (SEC-MALS) of YKV M2 results in a molecular weight of 397kD ± 0.1
suggesting the formation of oligomeric states consisting of many monomeric units, like more
than CPXV M2.
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The formation of multiple constitutive states is not conserved in all M2 analogs nor are
intermolecular disulfide linkages: A) Native-PAGE analysis of recombinantly expressed M2
analogs show two main bands for CPXV M2 and WR M2L, indicative of at least two
codominant states. The single MYXV M2 band would suggest the formation of one state, while
YKV M2 runs significantly higher suggesting high oligomerization (pI=6.56). C) Nonreducing/Reducing SDS-PAGE analysis of recombinantly expressed M2 analogs. CPXV M2 and
VACV WR M2L show clear high molecular weight bands that reduce to monomers when
reducing agent is added. Howver, MYXV M2 analysis reveals a monomeric band in both the
reduced and non-reduced sample signifying a distinct oligomerization method from CPXV M2.
YKV reduces to monomeric band when reducing agent is present, but non-reduced sample shows
no clear band for a higher molecular weight oligomer. It is possible YKV does not enter gel.
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M2 analogs conserve B7 binding capability and inhibit ex vivo T cell costimulation in a
species-specific fashion A) Flow cytometry histogram traces show cell surface staining by
CPXV M2 (cyan), VACV M2L (orange), MYXV M2 (green), and YKV M2 (red) against mouse
embryonic fibroblasts (MEFs) expressing either human B7.1, human B7.2 (top), murine B7.1, or
murine B7.2 (bottom). An unrelated PIE protein, CPXV C8L, was used as a negative control
(grey). Appropriate anti-B7 antibody was used as a positive control (black). CPXV M2 and
MYXV M2 robustly stain surfaces of MEFs expressing hB7.1 and hB7.2. VACV M2L positively
stains hB7-1 and mB7.1 expressing MEFs, but interacts with B7.2 expressing cells to a lesser
extent. YKV M2, along with CPXV M2, shows robust staining of mB7.1 and mB7.2 expressing
MEFs. Each of these possible interactions was assessed via SPR to confirm binding (S1). B) Tcell activation assays show that only M2s capable of binding mB7-2 (YKV M2 and CPXV M2)
effectively block mB7-2 mediated costimulation. Splenic T cells were isolated from B6 mice and
co-cultured with mB7-2 expressing MEFs. In the presence of recombinant analogs [CPXV M2
(cyan), VACV M2L (orange), MYXV M2 (green), YKV M2 (red)], T cell receptors were
stimulated using anti-CD3 antibody. Surface mB7-2 of co-cultured MEFs would then provide
costimulatory signal for activation. IL-2 production, a functional readout of T cell activation, was
measured via ELISA. Controls show that neither MEFs or T cells (+anti-CD3) result in IL-2
production alone, but only when co-cultured. As an additional control, anti-mB7-2 antibody is
able to arrest IL-2 production. Similarly, no activation is seen when CPXV M2 or YKV M2 is
present. VACV M2L nor MYXV M2 result in significant reduction of IL-2 production by T
cells.
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SPR analysis confirms species specificity amongst M2 analogs, and reveals the conservation
of B7.2 preference over B7.1 by MYXV and YKV M2, but not VACV WR M2. A) VACV
WR M2 binding to hB7.1. shows strong interection with significant half-life. B) VACV M2
displays fast kinetics in hB7.2 interaction. C) VACV WR M2 again strongly associates with
mB7.1 displaying its own preference for B7.1 over B7.2. D) MYXV M2 binds humanB7.2 with
slightly less affinity than CPXV M2, but displays very weak interaction with human B7.1 (data
not shown; Table 1). E and F) YKV binds mB7.1 and mB7.2 with low µM affinity, but has a 2fold higher interaction half-life with mB7.2.
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Low resolution cryo-EM analysis of MYXV M2 reveal formation of lone, constitutive
pentamers A) 2D class averages of MYXV M2 in complex with hB7.2 show the formation of
constitutive pentamer oligomeric states. Using RELION software, 289,502 individual particles
were grouped into 200 classes and averaged based on their structural characteristics and view
orientation. B) FSC plot for 3D reconstruction with resolution at FSC=0.5 and FSC=0.143
highlighted. C) Top, side, and bottom views of 3D envelopes of MYXV M2 in complex with
hB7.2. 2D class averages, containing a total of 74,497 particles, were grouped. These particles
were used to generated an ab intio 3D model that was later refined to a resolution of 4.35Å in C5
symmetry. Local resolution is depicted by color ranging from 4.3Å-6.1 Å. 80Å scale bar is
positioned below all orientations.
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Conservation based sequence analysis can direct mutagenesis to ablate murine B7.2
binding Sequence alignment was generated using the EMBL-EBI Clustal Omega online
alignment tool. Alignment was manually assessed for residue conservation. Red circles identify
the primary sequence positions of the nine residues NOT conserved between CPXV M2 and WR
M2L. Cyan triangles denote positions of the two residues not conserved from CPXV M2 to WR
M2L, but that are conserved between CPXV M2 and YKV M2. These residues were predicted to
be necessary for murine B7-2 binding and subjected to mutagenesis. Yellow highlighted
positions illustrate strict conservations across M2 analogs. Blue box outlines depict regions of
shared residue chemistry. Alignment illustration was generated using using ESPript 3.0
(http://espript.ibcp.fr). B & C) CPXV M2 mutations H145A and K146L result in specific
ablation of murine B7-2 binding with kinetic effect on binding of human B7-2. SPR was used to
analyze the interactions between CPXV M2 H145A K146L (CPXV M2Mut) and hB7-2 (B) or
CPXV M2Mut and mB7.2 (C). (D) T cell activation assay shows that CPXV M2Mut has lost ability
to block mB7-2 mediated T cell IL-2 production.
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Poxvirus strain distribution of M2, predicted-M2, and M2-like ORFs
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Summary of dissociation constants for each M2 analog and their respective ligands
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Summary of dissociation constants for each M2 analog and their respective ligands
analyzed using the 2:1 HL binding model
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Summary of cryo-EM collection data for MYXV M2 in complex with hB7.2
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Chapter 5: Cryo-EM processing for
unique/complex structures
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5.1 cisTEM vs Relion (2019)
RELION106,107 and cisTEM124 are the two prominent software packages for processing
cryo-EM data. RELION provides multiple tools/options for processing EM data while cisTEM
offers a very user-friendly interface and streamlined process. Additionally, cisTEM has a built-in
particle picker while RELION requires users to manually identify and select particles. These
hand-picked particles can then be used to “auto-pick” similar particles. This presents unique
challenges for smaller and densely packed molecules that can be overcome by pairing the
crYOLO108 particle picker with RELION processing. crYOLO can also be optimized or
“trained” to increase efficiency of picking for a specific data set. Each software package has its
own strengths and weaknesses that will make either package the best choice for some users and
not others.

5.1.1 Processing EM data using cisTEM
For those new to cryo-EM data processing, cisTEM offers a user-friendly graphical user
interface and streamlined process for data analysis (Figure 1). Additionally, cisTEM is
optimized to run on CPUs eliminating the need for graphics processors. The software also scales
for usage on laptop computers to large clusters enabling scientists with fewer computational
resources to successfully generate cryo-EM structures. Using a matched filter based approach
described by Sigworth125, cisTEM incorporates an automated reference-free particle picker. This
is particularly useful for data sets with densely packed particles or particles where little contrast
against solvent is observable by manual inspection. The combination of the user-friendly GUI,
CPU use, and the automated particle picker makes cisTEM a useful tool for streamlined data
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processing on inexpensive systems. With a simpler processing pathway, cisTEM can be used to
quickly analyze data sets by relatively inexperienced users.
Processing using cisTEM also has some drawbacks. Streamlined data processing means
less options for user input at certain steps. Specifically, the cisTEM particle picker cannot be
trained for a specific data set, there is no suitable method for classifying particles based on a 3D
presentation, and local resolution cannot be readily represented on a 3D volume directly from
cisTEM.

5.1.2 Processing EM data using RELION
Processing data in RELION is more of an iterative process in comparison to cisTEM.
There are numerous tools/options for processing EM data, at multiple steps, that can provide
parallel results (e.g CTFFind vs gCTF). RELION allows the user to more selectively process
cryo-EM data (Figure 2). 3D classification of 2D sorted particles provides an additional level of
data optimization. This additional step can reduce heterogeneity among selected particles and
increase resolution of final EM map. This is particularly important for sample that exist in
multiple oligomeric/organizational states. Bayesian polishing in RELION includes further data
manipulation in a way that captures significantly more initial motion than preexisting particlepolishing methods126. High-resolution data from the first few movie frames can be obtained
which eliminates the need to discard the first few movie frames127. These additional attributes
make processing EM Data using RELION more complex than cisTEM. However, the multiple
options for user input allows for more intricate data processing.
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The lack of a reference-free particle picker can make particle picking needlessly difficult
in RELION. Data sets with poor contrast or dense packing will be less efficiently processed due
to the likely human error during manual picking. Using crYOLO108, the trainable particle picker,
particles can be picked out of micrographs using GPU acceleration. These particles can then be
imported into RELION for further processing. While this process works well, it does require
simple command line input. Data processing through RELION will often require use of
command line interface for both trouble shooting and maximizing use of RELION tools. This
can make data processing slower, but often results in better structure determination for complex
samples.

5.2 Processing EM data sets for protein samples existing as
multiple, oligomeric states
CPXV M2 exists as hexamers and septamers inseparable via size-exclusion or ion
exchange chromatography. Proteins that exists as multiple states present unique challenges for
EM data processing. Prior to EM analysis, other quantitative analysis should be performed on
protein sample to determine as much preliminary information as possible. This information can
be used to optimize sample preparation and data processing. Multiple 2D classifications will
often have to be run to separate particles efficiently enough to be manually grouped for further
processing. 3D classifications can further help in separation of homogenous particle groups. Poor
signal-to-noise cause by heterogeneity in particle subsets can negatively impact resolution of
final EM map. Multiple iterations of 2D and 3D classification can result in a significantly
reduced particle subset. Therefore, multiple data sets may be combined to increase subset
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particle size using the most homogeneous molecules. More “good” particles will likely increase
resolution of EM map.

5.2.1 Preliminary information needed for particle picking
Certain characteristics should be always explored for samples before EM analysis, but
especially for heterogeneous proteins. Prior to cryo-EM, SAXS, SEC-MALS, negative stain-EM,
and SDS-PAGE was used to analyze CPXV M2 alone and in complex with hB7.2. This
information was used to estimate size and shape of CPXV M2/B7 complex. These estimations
were then used as a starting point for parameters necessary in sample preparation, particle
picking, classification, and map refinement.

5.2.2 Manual separation following 2D classification
Following 2D classification, homogeneous groups of heterogeneous samples should be clearly
distinguishable in 2D classes. Multiple iterations of 2D classification may be used to obtain
desired level of separation. The likelihood of solving high resolution structures decreases as
heterogeneity increases in particle subsets. Less can often be more in EM data processing.
Reducing heterogeneity can often result in better resolution even with less particles. Superior
particle separation should be prioritized over particle number. However, multiple data sets can be
combined to overcome limitations caused by strenuous classification in heterogeneous sample
data sets.

5.2.3 Combining data sets
Refining the CPXV M2/hB7.1 septamer map presented unique challenges. Using only particles
from one data set, the septamer 2D classifications displayed an orientation bias with mostly top
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views. This data set also resulted in a relatively low number of septamer particles. Combining
two data sets produced enough separated septamer molecules to refine the EM map. Repetitive
2D classifications also allowed for better separation resulting in different orientation views
necessary to generate a high-resolution EM map.
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5.3 Figures

cisTEM Graphical User Interface
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RELION 3.0.7 Graphical User Interface
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Chapter 6: Discussion
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6.1 CPXV M2 plays a physiological role during viral
infection
These studies clearly demonstrate that the cowpox virus encoded M2 proteins is secreted during
infection, interacts with cell-surface human and mouse B7.1&2, and subverts T cell
costimulation both in vitro and in vivo. Ex vivo experiments demonstrate recombinant M2 and
virally expressed M2’s ability to significantly hinder T cell activation mediated by B7.1&2
molecules. Additionally, the discovery of preferential binding of murine B7.2 over mB7.1
demonstrates intricate immunomodulation by CPXV. As the literature suggest a more dominant
role in T cell activation for B7.2 and an inhibitory role for B7.1, the exploitation of this axis is
evolutionarily cunning. In theory, viral techniques and proteins can be used to further therapeutic
knowledge for a host of disorders and complications. Investigation of the role of B7
costimulatory molecules in immune cell regulation have enabled therapeutic strategies for
transplant rejection and certain autoimmunity disorders128,129. Notably, soluble CTLA-4-Ig
fusion protein (abatacept) is capable binding B7.1&2 and has proven efficacious in relieving
symptoms of several autoimmune diseases including rheumatoid arthritis130,131. However, unlike
CPXV M2, CTLA-4-Ig provides no selectivity in T cell receptor blockade which may cause
negative side effects reported in some cases132. In this context, once CPXV M2 mechanism of
action is fully characterized, new therapeutic concepts may become available.

6.2 M2 directly competes with CTLA-4/CD28 for binding B7
molecules, but shows selective disruption of CD28/B7.2
interaction
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Cowpox virus is the only orthopoxvirus that encodes both a T4 protein (CPXV203) and tap
inhibitor (CPXV012) which act in concert to sabotage MHC-I presentation48–50. While both
proteins exhibit significant physiological importance, neither strategy affects cross-presentation
which likely drives T cell priming133. Here, it is clearly demonstrated that CPXV can sabotage T
cell activation via blockade of costimulation with the secreted M2 protein. Explicitly, M2 has
been optimized to take advantage of distinct B7.1/B7.2 roles in the murine system. The increased
interaction time with mB7.2 likely invokes M2’s preferential blockade of mB7.2-mediated
costimulation. As visualized via high resolution EM data, CPXV M2 binds human B7.1 and B7.2
in a manner that occludes CTLA-4 and CD28 binding sites providing evidence of direction
competition. Additionally, CPXV likely uses oligomerization to increase interaction with cell
surfaces at the point of secretion. CPXV M2 has shifted key cysteine residues to adapt the unique
disulfide bonding pattern of the PIE domain to allow intermolecular disulfides and thus
oligomeric ring formation. Intriguingly, M2 or M2-like ORFs are distributed amongst at least 19
poxvirus genomes45, most of which have no known mechanism for MHC-I downregulation.
Ectromelia virus encodes no recognizable M2 and invokes a considerably stronger virus-specific
CD4+ T cell response in comparison to vaccinia virus (VACV) WR which encodes a M2 protein,
M2L134. A recent study also reported that VACV Copenhagen strain M2 can also bind B7
ligands135. As M2 is not present in attenuated VACV strains (Modified vaccinia virus Ankara,
Acam3000), these findings also have implications for design of poxvirus-based vectors.
Specifically, deletion of M2 ORFs could increase T cell response. Further exploration of the PIE
domain family and M2 subfamily is needed to fully establish this as a conserved function.
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6.3 M2 is conserved across many poxviruses and likely has
conserved function of T cell costimulation blockade
At this time, we have definitively shown that B7 binding functionality is not unique to CPXV
M2, but is conserved by at least three other poxvirus M2 analogs. The conservation of function
illustrates the importance of M2’s role in T cell regulation and may be even more crucial in virus
that have now known mechanism to down regulate MHC-1. Importantly, YKV and MYXV M2
also display preferential binding of B7.2 over B7.1. The continued exploitation of these ligands
in terms of their not-so-overlapping roles likely allows poxvirus M2s to specifically block
activating costimulation leaving CTLA-4 unchecked. As seen with the mutagenesis studies,
continued structure and sequence analysis will help determine specific determinants of
preferential interaction vs a less preferred B7 interaction. Contrarily, this information can be
used to predict B7 interfaces for M2 proteins as well. Further investigating this family of proteins
may drive new solutions for existing autoimmune disorders that lack targeting specificity seen
here.
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